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1. SUMMARY 
 
Cancer is a genetically complex disease where cellular metabolism plays a key role on 
its establishment. In order to generate ATP-derived energy from our dietary intake, 
oxidation-reduction reactions are ultimately essential. The oxidation of such nutrients 
generate reduced cellular cofactors where NADH is listed as one of the most important 
due to its essential role within non-oxidative glucose degradation. This non-oxidative 
degradation is known as anaerobic glycolysis. 
Tumor initiation process that eventually sets the basis to Cancer disease is a multistep 
process. Every single feature involving the biology of the tumor phenotype have in 
common NAD+ pool recycling dependence as a main electron exchanger within 
oxidation-reduction reactions that they rely on. 
Nicotinamide phosphoribosyl transferase (NAMPT) is the rate-limiting enzyme of the 
Salvage pathway in cellular NAD+ biosynthesis. This pathway is the main source for NAD+ 
synthesis. As a consequence, this enzyme plays a key role in NAD+ pool maintenance, 
recycling and homeostasis.  
NAMPT is expressed in all tissues, with higher levels in bone marrow, liver and muscle 
myocytes, where the metabolic requirements are higher. NAMPT is also over-expressed 
in many cancer types. These include breast, colon, prostate, thyroid, stomach and 
some hematological cancers. In some cancer types like sarcomas and gastric, thyroid 
and prostatic carcinomas, NAMPT correlates with enhanced tissue invasion capability. 
Besides, NAMPT expression also correlates with enhanced metastatic potential and 
greater chemo resistance capability. 
In this work we decide to further analyze NAMPT role in cellular proliferation rate 
processes and apoptosis evasion as well as studying the molecular mechanism 
underlying NAMPT, which may be ultimately linked to the aforementioned processes. To 
this end, we explore pathways where NAD+ dependent deacetylation, ADP-ribosylation 
and metabolic regulation may play an important role in Cancer. For this, we choose as 
a model two tumors with different origins, an epithelial one (colon cancer) and a 
mesenchymal one (glioblastoma). 
We find that in both cancer types, glioma and colon cancer, NAMPT overexpression is 
a poor prognosis factor regarding patient survival. 
We find in every single analyzed model, either in vivo (human tumors and xenografts) or 
in vitro (cell lines), that NAMPT over expression results in a increase of tumorigenic 
properties such: increased rate of growth, increased invasiveness, increased resistance 
to cell death, and an increase in cancer stem cell properties. 
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Furthermore, we have found that NAMPT overexpression results in an increase of the 
cancer stem cell phenotype, leading to the transcription of the main core of genes 
driving pluripotency and inducing cell dedifferentiation. Besides, NAMPT over expression 
promotes epithelial-mesenchymal transition, crucial step in metastases development. 
For this, NAMPT associates with the activation of main signaling pathways controlling 
cancer stem cell like properties: Notch, Hippo, Sonic and Wnt. This phenotype is 
partially achieved as a consequence to the metabolic support given by NAMPT, 
ultimately acquiring a higher chemo resistance to treatments. In fact, many cellular 
detoxifying processes and DNA repair systems rely on NAD+ pool recycling. Altogether, 
these data reinforce the hypothesis that NAMPT may be a potent oncogene involved 
in different cellular processes helping to develop and maintain the tumor phenotype. 
Indeed, the tumor phenotype mediated by NAMPT has a major contribution through 
metabolic reestablishment of NAD+ pool recycling, in particular through its metabolic 
product Nicotinamide Mononucleotide (NMN). 
In all cases we have found a better treatment response to standard treatment for 
glioma and colon cancer, using the NAMPT inhibitor, with great results over toxicity 
induced directly to cancer stem cells, recovering chemo sensibilization. 
Altogether, these data indicate that NAMPT can be applied on the clinic as a 
therapeutic marker in these cancer types, using personalized treatments in either 
combination or monotherapy, being demonstrated a potential therapeutic effect over 
cancer stem cells. 
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2. RESUMEN EN ESPAÑOL 
 
El cáncer es una enfermedad genética compleja donde el metabolismo juega un 
papel fundamental. Las reacciones de reducción-oxidación son fundamentales para 
generar energía en forma de ATP desde los nutrientes que adquirimos en la dieta. La 
oxidación de dichos nutrientes genera cofactores reducidos, donde el NADH es uno 
de los más importantes al ser un cofactor esencial en la degradación no oxidativa de 
la glucosa. Esta degradación no oxidativa se conoce como glicólisis anaerobia.  
El  proceso  de  patogénesis  o  iniciación  tumoral  que da  lugar  al  cáncer  es  un 
proceso multifásico. Todas  las  características  del fenotipo tumoral  tienen  en  común  
la  dependencia  del  reciclaje de NAD+ como principal intercambiador de electrones 
en las reacciones de reducción-oxidación de las que dependen.  
La nicotinamida  fosforribosil  transferasa  (NAMPT)  es  el  enzima  limitante  de  la  vía  
de rescate  de  generación  del  NAD+. Esta  vía  es  el  centro  de  actividad  
mayoritaria  de  síntesis   de   NAD+   celular.   Por   ello   este   enzima   es   el   mayor   
contribuyente   al mantenimiento, reciclaje y homeostasis de NAD+. 
NAMPT se encuentra expresado en todos los tejidos, con mayores niveles en médula 
ósea, hígado y células de fibras musculares, donde el aporte energético es mayor. 
NAMPT se encuentra  sobreexpresado  en  muchos  tipos  de cáncer.  Estos  incluyen  
cáncer   de   mama,   colon,   próstata,   tiroides,   estómago   y   algunos   tipos   de   
cáncer hematopoyéticos. En algunos tipos de cáncer, como los sarcomas y los 
carcinomas gástricos, tiroideos y prostáticos, NAMPT correlaciona con una mayor 
capacidad invasiva del tumor.  Además, la expresión de NAMPT también  correlaciona  
con  un  mayor potencial metastásico y mayor resistencia a la quimioterapia. 
En este trabajo decidimos  analizar  en profundidad  el papel de NAMPT en  los 
procesos de proliferación cellular, “stemness” y evasión de la apoptosis así como 
estudiar el  mecanismo molecular a través del cual  NAMPT puede  intervenir  en  estos  
procesos. Para ellos nos centramos en vías  donde  la  desacetilación, ADP  ribosilación  
y  la  regulación  del  metabolismo  dependientes  de  NAD+  juegan  un papel 
importante. Elegimos como modelo dos tumores de origen diferente, uno epithelial 
(cáncer colorectal) y otro de origen mesenquimal (glioblastoma). 
Encontramos que tanto en glioma como en cáncer de colon, la sobreexpresión de 
NAMPT es un factor de mal pronóstico en la supervivencia del paciente. Hemos 
encontrado que en todos los modelos analizados, tanto in vivo (tumores humanos y 
xenoinjertos) como in vitro, la sobreexpresión de NAMPT dió lugar a un incremento de 
las propiedades tumorigénicas tales como aumento de la velocidad de crecimiento, 
incremeneto de la capacidad de invasión, incremento a la resistencia a muerte 
celular y a un incremento de las propiedades de célula madre del cáncer. 
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Hemos encontrado que, además, la sobreexpresión de NAMPT provoca un incremento 
del fenotipo de célula madre del cáncer, induciendo la transcripción del núcleo de 
genes que mantienen la pluripotencia e inducen desdiferenciación celular, 
promoviendo además la transición epitelio-mesénquima, paso crucial en el desarrollo 
de metástasis. Para ello, la expresión de NAMPT asocia con la activación de 
principales vías de señalización que median el fenotipo de célula mádre del cáncer: 
Notch, Hippo, Sonic Hedgehog y Wnt. La quimioresistencia a fármacos se debe, en 
parte, al aporte metabólico producido por NAMPT. son capaces de adquirir una 
mayor quimioresistencia a fármacos. De hecho, muchos de los procesos de 
detoxificación celular y reparación del ADN son dependientes de NAD+. Esto refuerza 
la hipótesis de que NAMPT es un potente oncogén implicado en diversos procesos 
celulares que ayudan al desarrollo y mantenimiento del fenotipo tumoral. 
El fenotipo tumoral mediado por NAMPT tiene una principal contribución a través del 
restablecimiento metabólico de la reserva y reciclaje de NAD+, en particular gracias al 
restablecimiento mediado por su producto enzimático, la nicotinamida 
mononucleótido (NMN).  
En todos los casos hemos encontrado una mejor respuesta a los tratamientos estándar 
para Glioma y Cáncer de Colon en combinación con la inhibición de NAMPT, con 
importantes resultados sobre la toxicidad inducida directamente a las células madre 
del cáncer. 
Todos estos datos indican que NAMPT puede aplicarse en la clínica como un diana 
terapéutica en estos tipos de cáncer, en tratamientos personalizados tanto en 
monoterapia como en combinación, habiendo demostrado un potencial efecto 
terapéutico sobre  las células madre del cancer in vitro. 
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3. ABBREVIATIONS 
 
AA: Anaplastic astrocytoma 
ATP: Adenosine triphosphate. 
BBB: blood-brain barrier.  
Bp: base Pairs. 
cDNA: Complementary DNA. 
CIC: Cancer initiating cell.  
CIMP: CpG island methylation phenotypes.  
CIN: Chromosomal instability.   
DMEM: Dulbecco modified Eagle's minimal essential medium. 
DNA: Deoxyribonucleic acid. 
EDTA: Ethylenediaminetetraacetic acid. 
EGFR: Epidermal growth factor receptor.  
EMT: Epithelial-mesenchymal transition  
FACS: Fluorescence-activated cell sorting. 
FAD: Flavin adenine dinucleotide. 
FAD: Flavin Adenine Dinucleotide. 
FADH2: Reduced form of flavin adenine dinucleotide. 
FBS: Fetal bovine serum. 
FMN: Flavin mononucleotide. 
GBM: Glioblastoma 
GEO: Gene expression omnibus 
H-E: Hematoxylin and eosin stain 
HIF-1: Hypoxia-inducible transcription factor 1. 
IDH1: Isocitrate dehydrogenase 1.  
IHC: Immunohistochemistry. 
IL-7: Interleukin 7.  
iPSC: Induced Pluripotent Stem Cells 
kDa: kilodalton. 
L-Trp: Tryptophan. 
LB: Luria-Bertani medium for growth of bacteria. 
LDHA: Lactate dehydrogenase A. 
M&M: Materials and Methods. 
mRNA: Messenger RNA. 
MSI: Microsatellite instability.  
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NA: Nicotinic acid (aka Niacin). 
NAAD: Nicotinic acid adenine mononucleotide. 
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NAD: Nicotinamide adenine dinucleotide. 
NADH: Reduced form of nicotinamide adenine dinucleotide. 
NADP: Nicotinamide adenine dinucleotide phosphate. 
NAM: Nicotinamide. 
NAMN: Nicotinic acid mononucleotide. 
NAMPT: Nicotinamide phosphoribosyl transferase. 
NAPT: Quinolinate phosphoribosyl transferase. 
Nb: Neuroblastoma 
NCBI: National center for biotechnology information  
NF-kB: Nuclear factor kappa beta.  
NF1: Neurofribomine 1.  
NGS: Next generation sequencing technology.  
NMN: Nicotinamide mononucleotide. 
NMNAT: NMN adenylyltransferase. 
NR: Nicotinamide riboside. 
OXPHOS: Oxidative phosphorylation. 
PAF: adenomatous polyposis.  
PARPs: Poly-ADP-ribose polymerases.  
PBEF: pre-B cell colony-enhancer factor. 
PBS: Phosphate-buffered saline. 
PDGFRA: Platelet-derived growth factor alpha receptor.  
RNA: Ribonucleic acid. 
RPMI: Roswell park memorial institute medium. 
RT-PCR: Reverse transcription polymerase chain reaction. 
SDS: sodium dodecyl sulfate. 
SFC: Stem cell factor.  
shRNA: small hairping RNA. 
SIRT: Silent mating type information regulation 2 homolog. 
TCGA: The cancer genome atlas. 
TMZ: Temozolomide  
WB: Western blot. 
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4. INTRODUCTION 
4.1. Biological oxidation-reduction reactions. 
 
Living cells require ATP-derived energy to both sustain and perform their functions. Cells 
use the chemical energy stored in the nutrients in order to generate ATP, which is a 
required molecule to develop physiological functions like cellular biosynthesis, cell 
contraction and mobility, etc [1]. In order to generate ATP, nutrients such as 
carbohydrates, fatty acids or proteins are degraded by exergonic oxidative 
degradation processes using catabolic pathways and thus, releasing energy. The 
oxidation of these nutrients will generate reduced cellular cofactors like: NADH, FADH2, 
etc. These cofactors yield their reduction equivalents to the molecular O2 through the 
mitochondrial electron transport chain, where most of the cellular ATP is generated [2]. 
There are two major types of oxidation-reduction cofactors: nucleotide pyridines, which 
contain nicotinamide, a member of the B vitamin complex, as an essential part of its 
structure. There are two coenzyme forms based on nicotinamide: nicotinamide 
adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate 
(NADP+) [3-6]. They both participate in oxidation-reduction reactions catalyzed by 
dehydrogenases. The second major type of cofactors, the flavins nucleotides: flavins, 
especially riboflavin, is part of vitamin B2, being an essential part of this coenzyme. It is 
presented in two coenzyme forms: flavin mononucleotide (FMN) and flavin adenine 
dinucleotide (FAD). Both forms participate in oxidation-reduction reactions catalyzed 
by dehydrogenases and oxidases. The flavin Nucleotides work with enzymes 
(Flavoproteins) that subtract two atoms of hydrogen from adjacent carbons, giving 
unsaturated compounds as in the case of succinate dehydrogenase. The flavin 
nucleotides are often found as prosthetic groups and act between either a substrate 
with another coenzyme or between two coenzymes [7, 8]. 
 
4.2. Reduction-oxidation processes and cancer. 
 
Cell respiration and most of cellular signaling processes rely on oxidation-reduction 
reactions. These reactions often rely on the reduction of nicotinamide adenine 
dinucleotide (NAD+) to NADH and the oxidation of NADH to NAD+. Imbalances in the 
oxidation-reduction reactions are directly linked to several diseases including cancer, 
therefore, maintaining the balance of these reactions is critical [9-11]. 
 
The process of pathogenesis or tumor initiation that results in cancer is a multiphasic 
process. This process comprises the acquisition of certain characteristics that include 
independence to growth signals, insensitivity to cellular anti-proliferative signals, 
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resistance to apoptosis, unlimited replicative potential, increased vascularization, 
increased invasiveness to adjacent tissues, immune system evasion and deregulation in 
tumor metabolism [12]. All these tumor characteristics have in common the 
dependence of the recycling of NAD+ as the main electron exchanger in the 
reduction-oxidation reactions on which they depend. 
 
4.3. The role of NAD+ in cellular metabolism. 
 
NAD+ is a water-soluble coenzyme that plays a key role on reduction-oxidation 
reactions on cellular metabolism [13]. It is, in fact, a universal electron transporter 
leading to produce ATP-derived energy in catabolic processes and thus, maintaining 
cellular homeostasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. NAD+ oxidative states. NAD+ is transformed into NADH when accepting a proton and two electrons. 
Alternatively, NADH can be transformed into a phosphorylated analog (NADPH) by the addition of an extra 
phosphate group. 
 
NAD+ is reduced to NADH in a reversible reaction when embracing a hydride ion (: H-, 
constituted by one proton and two electrons) from an oxidizable substrate (Figure 1). 
When NADH releases its electrons, the NAD+ form is recovered in order to behave as an 
enzymatic cofactor setting an electron donor-acceptor loop [14]. In this way, the free 
energy produced by the oxidation of the substrates is conserved. Both NAD+ and its 
near-analog Nicotinamide adenine dinucleotide phosphate (NADP+) are composed of 
 
 
5 
two nucleotides attached through their phosphate groups via a phosphoanhydride 
bond (Figure 1). 
 
NAD+ has a preferential role in catabolic reactions such as oxidation reactions like: 
combustion of pyruvate, fatty acids and α-ketoacids [15]. 
 
The processes where NAD+ acts are often spatially separated by cell organelles [16]. 
While those already aforementioned take place in the mitochondrial matrix, those ones 
involving reductive biosynthesis including fatty acids synthesis take place in the cytosol. 
Such spatial and functional specialization allows the cells to have two independent 
electron carriers’ pools involving different functions. More than 200 cellular enzymes 
using NAD+ or NADP+ have been described as acceptors of hydride ions from some 
reduced substrate to catalyze their reactions. That is why NAD+, its metabolism and 
recycling, play a fundamental role in the maintenance of cellular homeostasis [14, 16-
18]. 
 
4.4. NAD+ metabolism. 
 
Four major molecules are used as substrates for the synthesis of NAD+. These molecules 
are dietary tryptophan (L-Trp), nicotinic acid (NA), nicotinamide (NAM) and 
nicotinamide riboside (NR).  
 
Figure 2. NAD+ metabolism. Four major synthesis precursors (, dark blue) are divided between two major 
pathways. Left half – De novo synthesis pathway. Right half – Salvage Pathway. 
 
These four large molecules are involved in the synthesis of NAD+ through two major 
pathways: De Novo Pathway and Salvage Pathway. Some metabolic intermediates 
such as nicotinamide mononucleotide (NMN) might also stimulate the direct synthesis 
of NAD+ (Figure 2) [19, 20]. 
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4.4.1. De novo synthesis of NAD+. 
 
De novo synthesis of NAD+ takes place intracellularly in an eight-step reaction [21-25]. 
This pathway takes the L-Trp acquired through daily diet as a conversion molecule 
when obtaining NAD+. Tryptophan-derived quinolinic acid is produced and used by 
quinolinate phosphoribosyl transferase (NAPT) to form nicotinic acid mononucleotide 
(NAMN). NAMN is converted to nicotinic acid adenine mononucleotide (NAAD) in a 
NMN adenylyltransferase (NMNAT) -mediated reaction with ATP consumption [21]. 
There are three isoforms of NMNAT (NMNAT 1-3) with different tissue and cellular 
locations depending on the metabolic requirements [26]. NMNAT-1 is a ubiquitously 
expressed nuclear protein. NMNAT-2 is normally present in the golgi apparatus and the 
cytosol [27-31]. NMNAT-3 may be present in both the cytosol and mitochondrial 
compartments. The efficiency of obtaining NAD+ by dietary tryptophan is very low 
compared to that obtained by the Salvage pathway. 
 
4.4.2. NAD+ salvage pathway. 
 
This NAD+ synthesis pathway is also known as the Preiss-Handler pathway. In this 
pathway the NAD+ is generated from Niacin (Vitamin B3) in a three-steps reaction [19, 
20]. NAM can also be a precursor of NAD+ through its conversion to NMN by the limiting 
enzyme nicotinamide phosphoribosyl transferase (NAMPT). NMN acts as an 
intermediate by catalyzing the reversible addition of a ribose group from 5-
phosphoribosyl-D-ribosyl-1-pyrophosphate to NAM. In the mitochondrial respiratory 
chain, NADH acts as the main donor of electrons, which ends up in the generation of 
ATP by oxidative phosphorylation [32-34]. 
 
4.5 Distribution of NAD+ metabolism. 
 
The liver is the major organ involving NAD+ metabolic activity as it expresses all enzymes 
for either metabolism or recycling. Hepatic cells can actually convert all its precursors: 
NA, NAM and their ribosides as well as L-Trp. For that, NAMPT and NAPRT mRNA levels 
are particularly high in the liver, so this organ is one of the major NAD+ recycling and 
synthesis engine cores in humans [35, 36]. 
 
All tissues have the potential to at least convert NAM and NR into NAD+. That is why the 
NAMPT enzyme and at least two NMNAT isoforms are ubiquitously expressed in all cells 
and tissues. Some others, such as NMNAT2, are brain specific [37]. Other NMNAT 
isoforms are expressed in a greater proportion in the pancreas, thyroid gland and 
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lymphocytes [28]. In mammalian cells, the metabolism of NAD+ is compartmentalized. 
The formation of NAD+ from NMN takes place in the nucleus and in the mitochondria 
[32, 33, 38]. These two organelles are particularly important as the most important NAD+-
dependent intracellular signaling pathways occur in them.  
 
Figure 3. Scheme of cellular pathways using NAD+. (A) Main pathways using NAD+ (B) Major NAD+-mediated 
deacetylases controlling HIF-1 stabilization and Oxidative Stress Responses (ROS) 
 
The most important cytosolic NAD+ precursor for mitochondrial synthesis is NMN. 
Therefore, NAD+-dependent cellular processes are intimately linked to the most 
important molecular events that could lead to cancer: genomic alterations, metabolic 
imbalances and changes in the transcription patterns of candidate oncogenes or 
tumor suppressors. 
 
4.6. NAD+-dependent cell processes and signaling pathways. 
 
There are many processes controlled by NAD+ dependent enzymes (Figure 3A). 
Deacetylation and mono/poly ADP ribosylation are among the most important. This 
fact makes NAD+ a factor controlling a large number of signaling pathways ultimately 
contributing to cellular homeostasis. 
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4.6.1. Adjustments in tumor metabolism: the Warburg effect. 
 
In tumor cells, the preference of the glycolytic pathway against oxidative 
phosphorylation to obtain energy in the form of ATP even in the presence of oxygen is 
known as the Warburg effect. During glycolysis, glucose uptake and consumption takes 
place over ten times faster than in non-tumoral cells (Figure 4).  
 
Figure 4. Glycolytic flux scheme. (A) Normal Cells (B) Tumor cells. The arrows’ thickness indicates the relative 
flow of the reaction. 
 
Due to the initial lack of vascularity, which supplies oxygen to the tumor, tumor cells 
often suffer from a limited supply of oxygen (hypoxia). As a result, during tumor growth, 
tumor cells that are farther away from the nearest vessel become hypoxic and thus, 
depend on anaerobic glycolysis as the main source of ATP generation [39], generating 
lactate. To this end, hypoxia-inducible transcription factor (HIF-1) triggers the 
transcriptional activation of at least eight of the glycolytic enzymes, including lactate 
dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to lactate, A 
crucial step in the Warburg effect [40-42]. 
 
For decades, the Warburg hypothesis argued that tumor cells maintain greater use of 
lactate production over oxidative phosphorylation (OXPHOS) to obtain ATP even in the 
presence of oxygen (aerobic glycolysis). This led to the thought that tumor cells had 
damaged the OXPHOS pathway when it comes to generate ATP since oxygen was not 
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able to suppress lactate production in tumor cells [10]. It was later demonstrated that 
tumor cells are able to perform oxidative phosphorylation in a proportion similar to non-
tumor cells, which reinforces the dependence of the use of NAD+ on tumor metabolism.  
 
The Warburg’s metabolism has also been described in embryonic tissues with high 
division rate [43, 44]. This highlights the role of glycolytic metabolism in large-scale 
cellular biosynthesis programs required for cell proliferation. 
 
In the case of tumor cells this metabolism is stabilized in order to meet the high 
biosynthesis demand for essential building blocks like lipids, proteins and nucleic acids 
required in the accelerated proliferation and expansion of the tumor. To maintain this 
enhanced metabolism, tumors often require mutations in genes that stabilize HIF-1 and 
do not get degraded in the presence of oxygen. 
 
It has also been shown that there are two metabolic subpopulations in tumors: a 
subpopulation of tumor cells able to secrete lactate as waste (usually hypoxic) and 
another subpopulation that captures this lactate by recycling it to pyruvate for entry 
into OXPHOS. These two subpopulations act symbiotically: hypoxic cells rely on glucose 
to generate lactate preferentially as waste so that it is imported by the better 
oxygenated cells. This symbiosis reinforces the idea that tumors are highly dynamic 
entities in both structure and form, so the vascularization and energy supply is 
fluctuating and not static, so the tumor must be prepared to adapt itself metabolically 
reprogramming its pathways to obtain energy quickly and efficiently. For all this, tumor 
cells require high amounts of NAD+. Tumor cells, thus, maintain a preference and 
addiction over the Warburg effect to reinforce a metabolism that meets the high 
anabolic demand for tumor growth. Glucose itself has been shown to be insufficient to 
maintain cell growth and tumor proliferation. This is why many oncogenes and tumor 
suppressors have been shown to have an effect on the regulation of genes that 
encode enzymes that favor the conversion of glucose to lactate, requiring a greater 
contribution of NAD+ to support this whole process. 
 
HIF-1 induces transcription of enzymes for the realization of anaerobic glycolysis, so that 
an oncogenic transcription factor stimulates the transcription of enzymes that perform 
the metabolism of Warburg. This enables the tumor the ability to survive under stressful 
conditions adapting such cells to a characteristic tumor metabolic environment. 
 
Tumor cells often overproduce glycolytic enzymes insensitive to product inhibition such 
as hexokinase, monopolizing the produced ATP in the mitochondria and thus forcing 
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the conversion of glucose into glucose 6-phosphate, activating a constitutive cellular 
glycolysis. 
 
As a general mechanism the tumor cell uptakes more glucose, converting both 
pyruvate and lactate and favoring indistinctly the use of OXPHOS or the Warburg effect. 
In this process, tumor cells continuously recycle NAD+ and its reduced NADH form as 
required electron donors in the reduction-oxidation reactions (Figure 3B). 
 
4.6.2. Nicotinamide phosphoribosyl transferase (NAMPT). 
 
Nicotinamide phosphoribosyl transferase (NAMPT) is the limiting enzyme of the NAD+ 
Salvage Pathway. This pathway is the major NAD+ source in living cells. Therefore, this 
enzyme is the major contributor to NAD+ maintenance, recycling and homeostasis. 
 
NAMPT is a highly conserved protein among mammals. It was cloned and isolated for 
the first time in the organism Haemophilus ducreyi and it has been extensively studied. 
 
Figure 5. Location and structure of the NAMPT gene. Schematic figure of the long arm of human chromosome 
7. DNA gene region including introns and exons is shown. 
 
It was originally characterized as the human homologous protein pre-B cell colony-
enhancer factor (PBEF) [45, 46]. In its role as PBEF it acts as a cytokine, which stimulates 
early B cell formation in a synergistic effect with interleukin 7 (IL-7) and stem cell factor 
(SFC) [45, 47, 48]. 
 
The gene encoding NAMPT is found on human chromosome 7, specifically at the 
7q22.3 locus. The size of the gene within the DNA is 3.7 kilobases (kb) and contains 11 
exons and 10 introns that encode a coding DNA (cDNA) of 2.357 kb (Figure 5). The 
protein has a weight of 52 kilodaltons (kDa) and contains 491 amino acids (aa) [49]. The 
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protein lacks a cellular export signal and also contains 6 cysteine residues, so it has 
been suggested a structure of the same as zinc finger.  
 
In silico, up to thirteen messengers of different NAMPT RNAs (mRNA) are predicted by 
alternative splicing mechanisms, of which only four have been found at the biological 
level. Of the four, only the first messenger translating  into the 491 amino acid protein is 
able to make the conversion to its enzymatic product NMN, hence it is the one studied 
in this work.  
 
NAMPT is expressed in all tissues, with higher levels in bone marrow, liver and muscle 
fiber cells, where the energy intake is greater. 
 
The extracellular form of NAMPT, PBEF or Visfatin is known as extracellular NAMPT 
(eNAMPT, as opposed to intracellular NAMPT, iNAMPT), an adipocytokine that is 
expressed in visceral fat tissue and its circulating levels correlate with obesity. The 
extracellular role of NAMPT is unknown and could have a function of activation or 
silencing in signaling pathways within the cell other than those related to its enzymatic 
function such as NAMPT. 
 
As a limiting enzyme of the pathway which plays a key role in the maintenance of 
intracellular NAD+, NAMPT could be an oncogene contributing to the onset, progression 
and relapse of Cancer. 
 
4.6.2.1. NAMPT in cancer 
 
NAMPT is overexpressed in a broad range of solid tumors including colorectal, ovarian, 
breast, gastric, prostate, well-differentiated thyroid cancers, melanoma, gliomas and 
endometrial carcinomas [50-53]. Clinically, higher NAMPT expression is associated with 
worse prognosis correlating with tumor growth, metastases and cellular 
dedifferentiation in melanoma [54, 55].  
 
High levels of NAMPT have been found in hematological malignancies such as diffuse 
large B-cell lymphoma, Hodgkin’s lymphoma, follicular B-cell lymphoma and peripheral 
T-cell lymphoma. In these tumors, it does associate to a more aggressive malignant 
lymphoma phenotype [56] 
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Besides, NAMPT levels has been associated to increased chemoresistance to certain 
therapeutic agents such as doxorubicin, paclitaxel, etoposide, fluorouracil and 
phenylethyl isothiocyanate [57, 58] 
Many studies have shown that NAD+ depletion by NAMPT inhibition causes cell death 
through apoptosis. Many pro-apoptotic proteins were found activated when NAMPT is 
inhibited in leukemias, multiple myeloma, breast cancer, and lymphoma cells [59-66]. It 
has been found that NAMPT inhibition-mediated apoptosis requires functional 
apoptotic machinery because blocking apoptosis with several factors such as: L-type 
calcium channels with verapamil or nimodipine, capase 3 with Z-Asp-Glu-ValAsp-
fluoromethylketone, capase 9 with with Z-Leu-Glu-His-Asp-fluoromethylketone or the 
mitochondrial permeability transition with bongkrekic acid blocks the effect of NAMPT 
inhibition-mediated apoptosis [59, 66].  
 
Three NAMPT inhibitors (APO866/FK866, GMX1778 and GMX1777) entered clinical trials 
and completed phase I, however, further evaluation was discontinued primarily due to 
dose-limiting toxicities (ClinicalTrials.gov identifiers:  NCT00457574, NCT00724841, 
NCT00432107, NCT00435084, NCT00431912) 
 
Another enzymes of the salvage pathway have been suggested to be potential 
therapeutic targets in cancer. Mitochondrial NMNAT3 knockdown had minimal effect 
over mitochondrial NAD+ levels [30, 67, 68]. On the other hand, NMNAT2 cytosolic 
inhibition decreased mitochondrial NAD+ levels, suggesting that NAD+ in the 
mitochondrial is partially supported by NAD+ intake from the cytosol [68]. However, 
shortly after was found that NAMPT inhibition had no effect on mitochondrial NAD+ pool, 
discarding the previous theory and highlighting the role of NAMPT as the main potential 
target of the pathway in cancer by depleting NAD+ pool [32]. NAMPT inhibition seems 
to be particularly effective over cells harboring naturally high glycolysis [69] 
 
4.6.3. NAD+-dependent deacylases: sirtuins. 
 
Sirtuins are NAD+-dependent deacetylase enzymes. These enzymes establish a direct 
bridge between metabolic homeostasis and gene regulation. Sirtuins are able to 
directly regulate the catalytic activity of key metabolic enzymes. Some of these 
enzymes include mitochondrial and cytosolic acetyl-CoA synthetases [70, 71]. The main 
function of sirtuins is removing acetyl groups from lysine residues of the target proteins. 
During the deacetylation process, an ADP-ribose group is added to the acetyl group to 
produce O-acetyl-ADP-ribose. Both acetylation and ADP-ribosylation are post-
translational modifications affecting protein activity (Figure 3A). Sirtuins comprise a 
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family of seven members (SIRT1-7) that are capable of modulating processes such as 
cellular metabolism and mediate responses to cellular stress (Figure 3B). SIRT1 and SIRT2 
are involved in modulating gene expression [72, 73]. The absence of either alters 
cellular physiology by altering differentiation, maturation and senescence processes 
mediated by chromatin silencing mechanisms through deacetylation. SIRT1 activates or 
represses transcription through different types of deacetylations [74-78]: 
 
∞ Deacetylation H3 in the following lysine residues: 9 (H3K9Ac), 14 (H3K14Ac) and 56 
(H3K56Ac). 
∞ H4 deacetylation at the lysine residue 16 (H4K16Ac). 
∞ H1 binding histone at the lysine residue 26 (H1K26Ac). 
 
Deacetylation of SIRT1-mediated H2K9Ac / H4K16Ac / H1K56Ac induces chromatin 
silencing and transcription repression. Hypoacetylation of H3 / H4 tends to increase in 
certain hypermethylation markers such as H3K9Me2 / 3 and H4K20Me1 which are also 
associated with the silencing of chromatin. A well-studied case of the mechanism of 
action of sirtuins is the Combined action SIRT-SUV39H1 which triggers the deacetylation 
of H3K9Ac and increases the trimethylation in H3K9 [78]. 
 
SIRT1, SIRT3 and SIRT6 play a very important role in the regulatory axis of metabolism 
(Figure 4B) and inflammation processes [79]. SIRT6 is further able to self-regulate by 
modulating gene expression by NAD+-dependent ADP-ribosylation [80]. It plays a key 
role in the down-regulation of target promoters of nuclear factor kappa beta (NF- B) 
and HIF-1 (Figure 3B) causing it to be involved in stress response, aging and homeostasis 
processes of glucose metabolism [81, 82]. 
 
Therefore, Sirtuin’s family encompasses a spectrum of biological functions including 
gene silencing, DNA damage repair, cell cycle regulation and cell differentiation. 
Genes encoding sirtuins may be considered either oncogenes or tumor suppressor 
genes since sirtuins play a context dependent role in maintaining proliferative balance 
according to tissue type. This is due to its broad regulatory spectrum. Being proteins 
strictly dependent on NAD+, their functional regulation can also be controlled by direct 
regulation of intracellular NAD+ levels. 
 
4.6.3.1. Sirtuins in cancer. 
 
As mentioned, Sirtuins regulate a wide spectrum of biological processes. SIRT1 
deacetylates various substrates modulating activity of important histones, transcription 
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factors, DNA-repair factors and signaling proteins, thereby modulating the role as tumor 
suppressor or oncogene depending on the cancer type. It is predominantly nuclear 
and expressed in most mammalian tissues. Increasing the activity of SIRT1 either by 
specific drugs or by ectopic overexpression leads to different phenotypes in the 
following cancer models:  
- Tumor suppressor role: Breast [83, 84], liver [84], prostate [84], ovarian [84], skin 
cancer [85] as well as Glioblastoma [84], bladder [84] and oral squamous cell 
carcinoma [86]. 
- Oncogene role: Colon [87, 88], liver [89], thyroid cancer [90] as well as acute [91] 
and chronic [92] myeloid leukaemia cells. 
SIRT1 involving oncogene functions was originally found to deacetylate and repress the 
activity of the tumor suppressor p53 by attenuating p53-mediated apoptosis under 
conditions of DNA damage and oxidative stress [93, 94]. Besides, SIRT1 can also 
deacetylates and downregulates E2F1, a tumor suppressor which can drive cells to S 
phase but also induce apoptosis in response to oncogenic stress [95]. Another 
oncogenes can enhance SIRT1 expression. The transcription factor signal transducer 
and activator of transcription 5 (STAT5) binds to SIRT1 promoter and increases its 
expression [90]. The oncogenic tyrosine kinase fusion protein BCR-ABL also induces SIRT1 
expression in cells previously transformed by activated STAT5 [92]. In thyroid and 
prostate cancer, SIRT1 oncogenic activity has been proposed by driving MYC 
transcriptional programme [90]. 
 
Conflicting with these functions, SIRT1 also may be playing a role as a tumor suppressor. 
In breast and ovarian cancer with inactivating BRAC1 mutations, the formation of 
mammary tumors is partially explained by the lost of the positive regulation axis 
between SIRT1 and BRAC1, which is lost when cancer occurs. SIRT1 can also repress 
GLI1 and GLI2 (transcription factors in the Hedgehog signaling pathway) in 
medulloblastoma model [96]. 
 
The basis of this discrepancy requires further investigation. Whereas SIRT2, SIRT3, SIRT4 
and SIRT6 were found to be tumor suppressors, SIRT7 was found to be an oncogene in 
uterine, colon, kidney, ovarian and prostate cancer [83-114]. SIRT5 has been also 
proposed to be an oncogene in non-small-cell lung cancer [102]. It is worth to mention 
that SIRT6 was found to be an oncogene only in breast cancer. 
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4.6.4. NAD+-dependent ADP ribosylation: PARP proteins. 
 
Poly-ADP-ribose polymerases (PARPs) are NAD+-dependent enzymes that catalyze the 
transfer of ADP-ribose polymers to acceptor proteins (Figure 3A). Processes such as 
gene transcription, apoptosis, chromatin structure modeling, cell differentiation, DNA 
repair and stress responses appear to be partially regulated by PARP, suggesting a 
possible role of NAD+ in cancer prevention [115, 116]. Up to six PARP proteins have been 
identified with a considerable NAD+ consumption dependency. PARP1, however, is the 
most abundant protein of the six and its main function is detecting different types of 
DNA damage. PARP1 and NMNAT1 interact directly. Recent studies further claim that 
the active form of PARP1 regulates genomic stability, including mechanisms of cell 
survival and modulation of apoptotic signals.  
 
4.6.4.1. PARP proteins in cancer. 
 
As mentioned, PARP plays a key role in the repair of DNA single strand breaks (SSB) [117, 
118]. The structures of the first PARP inhibitors were built around an NAD+ mimetic core in 
order to prevent its enzymatic activity that is required to facilitate SSB repair. 
Consequently, PARP1 inhibition prevents NAD+ utilization, thereby preventing DNA 
repair and generating a potential block for DNA replication [117, 118]. Blocking SSBs 
repair may also trap PARP-DNA complexes, generating replication forks, resulting in 
deleterious double strand breaks (DSBs) [117]. Potentially, any cancer type could be 
benefited of PARP inhibition. Nonetheless, the breast- and ovarian-associated tumor 
suppressor genes BRCA1 and BRCA2 are the best-known disease-associated examples 
of defective components of homologous recombination repair (HRR), hence PARP 
inhibitors to induce cell death in BRCA-deficient cells through the concept of synthetic 
lethality demonstrated great results [119, 120]. Nowadays, the use of pharmacologic 
inhibitors of the catalytic activity of PARP1 and PARP2, has been an explored approach 
in the context of cancer therapy [121-130]. Altogether, PARP1 has shown a context 
dependent role, where it may well act as a tumor suppressor or oncogene, the main 
reason for which it has been found overexpressed in multiple cancers [131]. 
 
4.7. Colorectal cancer. 
 
Colorectal cancer is the third most common type of cancer in men and the second in 
women. Less than 20% of first-time diagnosed patients with metastatic colon cancer 
survive more than 5 years [132]. Thus, the therapeutic approach to colorectal cancer is 
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challenging because of its molecular complexity. Many patients develop refractory 
disease to all treatment lines from stages II to III and, eventually, to metastasis.  
 
The main causes of colon cancer are environmental risks and genetic events. 
Environmental risks include high-calorie diets rich in unsaturated fats and red meats, 
alcohol consumption and lack of physical activity. Colorectal cancer appears under 
three types of patterns: hereditary, familial and sporadic. The hereditary and familial 
partially root from germ line mutations. Hereditary colorectal cancer accounts for up to 
10% of newly diagnosed cases. Lynch syndrome and familial adenomatous polyposis 
(PAF) are diseases with a high risk of developing hereditary colorectal cancer. Familial 
colorectal cancer accounts for up to 25% of newly diagnosed cases. This type does not 
present any type of Mendelian inheritance nor a specific genetic etiology. Sporadic 
colorectal cancer is derived from somatic mutations. It is not associated with genetic 
inheritance and represents up to 70% of cases of colorectal cancer [133]. A small group 
representing 1-2% of annual cases are colorectal tumors derived from an inflammatory 
bowel disease [134]. 
 
These patterns of colorectal cancer make it a very heterogeneous and molecularly 
complex type of cancer [135-138]. Next generation sequencing technology (NGS) has 
made great strides in the field by making molecular categories. This technology has 
revealed that the number of mutations in this type of cancer is very high. Each 
colorectal cancer tumor carries at least 75 different mutations. The most accepted 
classification of mechanisms of appearance is subdivided into three categories: 
 
∞ Chromosomal instability (CIN). It represents 84% of cases of sporadic colorectal 
cancer. This category includes changes in the number and structure within 
chromosomes. These changes are mostly deletions, gains and chromosomal 
translocations [139]. 
∞ Microsatellite instability (MSI). It accounts for 13-16% of sporadic cases of colorectal 
cancer. This category includes error within DNA repair mechanisms by mismatch repair 
(MMR) and CpG island methylation phenotypes (CIMP). The latter mechanism 
encompasses cases of colorectal cancer that appear through epigenetic instability by 
promoter hypermethylation. In addition to promoter hypermethylation there is silencing 
of tumor suppressor genes [140]. 
∞ Serrated pathway. Colon cancer can also arise from hyperplastic polyps. These 
polyps are characterized by having serrated glands. It is estimated that 30,000 cases 
per year come from this category. The molecular basis of the sawed form presented by 
epithelial crypts is not entirely clear, although it has been associated with BRAF 
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mutations. Hyperplastic polymers with KRAS mutation instead of BRAF have a lower 
proportion or absence of serrated glands [140-142]. 
 
The overall survival of colon cancer is often associated with tumor stage, generally by 
the TNM criteria, which establishes degrees of depth for tumor penetration into the 
intestinal wall (T), number of nodes affected by the tumor (N) and presence or absence 
of metastasis (M). 
 
At the time of diagnosis, up to 14% of patients will be diagnosed in stage I. 28% in stage 
II. 37% will harbor stage III colorectal cancer and 21% will have metastatic disease. The 
distant organs to which colon cancer preferentially metastasizes, of which liver, lung, 
and brain are among the most common sites [143-145]. Each stage presents a 
heterogeneous molecular profile that implies a specific treatment in function of 
prognostic and predictive markers of response. This makes colorectal cancer a disease 
of difficult therapeutic approach because of its molecular complexity. 
 
The initial treatment of localized colorectal cancer is surgery and resection of the 
primary tumor next to the regional lymph nodes. Colon cancer is highly curable with 
surgery when it is detected in primary stages. When the disease spreads to regional 
ganglia, the possibility of recurrence increases markedly. In such cases adjuvant 
chemotherapy is used in the months following surgery. 
 
Conventional chemotherapy in the treatment of colorectal cancer combines 
Fluorouracil and leucovorin with oxaliplatin or irinotecan (In clinical this combination is 
known as FOLFOX / FOLFIRI) [146, 147]. Responses to these chemotherapeutics are 
generally good (response rates greater than 60%) but patients often fail to respond to 
these chemotherapeutics with a prognosis of overall survival not exceeding 20 months. 
 
Despite advances in the treatment of colorectal cancer, this disease remains incurable 
in its metastatic state. Once disseminated, the disease becomes essentially incurable 
and unresectable. In this state less than 5% of the patients survive more than 5 years 
[148, 149]. Many patients develop refractory disease to all treatment lines from stages II 
and III to eventually metastasize.  
 
Since NAD+ production may play a key role in colon tumor initiation, progression and 
relapse [153, 154]. NAD+ is known to be a co-substrate of mainly three protein families: 
ADP ‐ ribosyltransferases (e.g., PARPs), deacetylases (Sirtuins), and cADP ‐ ribose 
synthases (e.g., CD38) [150], NAD+ is considered a key mediator of chromatin 
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remodeling due to its co-association with the Sirtuins and PARPs and its direct binding to 
CtBPs [150-152]. Thus, Beyond its role as a metabolite, NAD-derivatives function as 
important cofactors in cellular redox reactions and as second messengers in several 
cellular processes. NAD exists in two forms, an oxidized (NAD+) and a reduced (NADH) 
form. NAD+ is essential for metabolism, energy production, DNA repair, and signaling in 
many types of cancer cells including colon cancer cells [150, 152]. The mechanisms of 
resistance are highly variable but all commonly use NAD+ in reduction-oxidation 
processes that contribute to the improvement in the DNA repair system and an 
increase in detoxification capacity [152].  Consequently, high levels of NAD+ have been 
associated with tumor chemoresistance [51, 150, 155, 156]. 
 
4.8. Gliomas. 
 
Gliomas are the most lethal and prevalent primary brain tumors in adults and are 
associated with a poor median survival time, which barely exceeds 12 months despite 
newly available treatments [157, 158]. These unsuccessful attempts to manage gliomas 
have stimulated research for more effective therapies. Several studies have highlighted 
the importance of intratumoral heterogeneity, which is driven by genetic and 
epigenetic effectors, to therapeutic responses and patient survival, especially in 
gliomas. Tumor heterogeneity is partially explained by the cancer-initiating cell (CIC) 
hypothesis, which states that a cellular hierarchy exists in some tumors with self- 
renewing CICs, generating the progeny that are responsible for tumor complexity [159, 
160]. CICs express certain stem cell markers and exhibit sustained self-renewal. CICs 
also display high radio- and chemoresistance, which contribute to tumor relapse 
following treatment [161-165]. Thus, targeting CICs offers a potential new treatment 
frontier for glioma control.  
 
Glioblastoma is classified as grade IV glioma according to the World Health 
Organization [166]. There are two types of glioblastoma: Primary and secondary 
glioblastomas. Secondary glioblastomas may develop from a low grade diffuse 
astrocytoma (Grade II glioma) or an anaplastic astrocytoma (Grade III glioma) (Figure 
6). Secondary glioblastomas represent 5% of the total cases. 
 
Primary glioblastomas represent 95% of the cases being the most frequent. The 
diagnosis of glioblastoma includes tumors of high mitotic activity, microvascular 
proliferation and / or necrosed area [167]. These characteristics are fulfilled by both 
primary and secondary glioblastomas. This makes the two types indistinguishable 
histologically [168]. 
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Glioblastomas represent 16% of brain tumors [168]. The incidence and risk is proportional 
to the age of the individual. It affects an average of 7.2 individuals per 100,000 adults 
aged 19 years and above. Its peak incidence, however, is found in individuals between 
74 and 84 years of age with an annual incidence of 14.6 individuals per 100,000 [168]. 
 
Glioblastomas are very fast growing tumors. Its growth is normally greater than its 
capacity of vascularization. This causes that tumor’s core is often necrotic. 
Glioblastomas are also 40% more frequent in men than in women. The overall survival of 
the patient diagnosed with glioblastoma rarely exceeds 12 months [157, 158]. The 
therapeutic strategy of glioblastoma consists of surgery followed by radiotherapy and 
chemotherapy. Glioblastomas are highly infiltrating tumors so that their complete 
surgical resection is virtually impossible. Virtually 100% of patients end up recurring in a 
peripheral area up to 2 cm from the initial focus. 
 
The standardized treatment of glioblastoma consists of radiotherapy along with an 
adjuvant treatment of temozolomide, a DNA alkylating agent capable of crossing the 
blood-brain barrier (BBB) [169]. Despite treatment, less than 5% of patients survive more 
than 5 years after diagnosis. 
 
It is commonly considered that glioblastoma originates from 5 different cell types [170]: 
neuronal stem cells, transit amplification cells, glial / neural progenitors, astrocytes, and 
oligodendrocytes (Figure 6). 
 
Alterations such as chromosomal aberrations, genomic rearrangements, and focal 
copy number aberrations can give rise to a cancer initiating cell (CIC) and eventually 
to a glioma. 
 
CICs are a subpopulation of cells that explain part of tumor heterogeneity. They are 
cells with capacity for multiple differentiation and self renewal [171-174]. They are 
responsible for tumor growth and hierarchical clonal development. They are able to 
regenerate a de novo tumor from a single cell. Its existence was suggested more than 
40 years ago but it was not until 1997 that they were confirmed in acute myeloid 
leukemia and later in solid tumors. CICs are associated with chemoresistance. The 
metabolism of NAD+ could play a relevant role in the mechanisms associated with 
chemoresistance in CICs and their maintenance mechanisms. 
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Figure 6. Gliomas’ origin cells and Glioblastoma’s classification. Origin cells and molecular classification of 
glioblastomas according to The Cancer Genome Atlas (TCGA). The thickness of the arrows indicates the 
relative flow of NAD+ consumption 
 
An unmonitored cluster of gene expression data from 200 gliablastoma samples from 
TCGA in 2011 established four subtypes of glioblastoma according to their molecular 
profile (Figure 6) [175, 176]. 
 
∞ Proneural. Characterized by abnormalities in platelet-derived growth factor alpha 
receptor (PDGFRA) or in isocitrate dehydrogenase 1 (IDH1). 
∞ Classic. Characterized by mutations in the epidermal growth factor receptor (EGFR). 
∞ Mesenchymal. Characterized by mutations in neurofribomine 1 (NF1) 
∞ Neural. It is not completely defined but contains amplification and overexpression of 
EGFR. (It has been found that the molecular markers defining the neural subtype of 
GBM could be contaminated with  normal neural tissue in the tumor margin, thus not 
representing a true subtype [175]) 
 
 
The mutational spectrum of glioblastoma is very varied. They are highly molecularly 
complex tumors. The number of coding mutations per tumor sample is utterly varied. 
The average is 53 mutations per tumor in a range ranging from 3 to 179 mutations [176]. 
The most frequent mutations in glioblastomas are PTEN (29%), TP53 (29%), EGFR (20%), 
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NF1 (9%), RB1 (8%), phosphatidylinositol-4,5-bisphosphate alpha catalytic subunit - 3-
kinase (PIK3CA; 7%), regulatory subunit 1 of 3-phosphoinositide (PIK3R1; 6%) and IDH1 
(5%) [177, 178]. 
 
A common feature of all subtypes of glioblastomas and other stages of malignant 
gliomas is glucose dependence as the main source of metabolic energy. Gliomas are 
highly metabolic and rely on glycolytic pathways [179, 180]. This is why most gliomas 
may have a strong dependence on NAD+ metabolism as the main intermediary in the 
reduction-oxidation reactions. Gliomas need enhanced metabolism to maintain such a 
fast growth. In the brain, high levels of NAD+ protect against cell death in the absence 
of glucose. This is why control over the NAD+ synthesis pathway and in particular over 
NAMPT could be a very promising therapeutic strategy in this type of incurable tumor 
up to date. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. OBJECTIVES 
 
 
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
5. OBJECTIVES 
 
The main goal is to study the relevance of NAMPT in human tumors. To this end we 
divided the goal in the following specific aims: 
1. To study the phenotypic effects induced by NAMPT overexpression or specific 
downregulation. 
2. To Identify the molecular mechanisms through which NAMPT could initiate or 
promote the tumor process. 
3. To study the relevance of NAMPT in patient prognosis and as a therapeutic 
target in cancer 
As experimental set ups we chose two different tumor models, one derived from 
epithelial cells (colorectal cancer) and another derived from mesenchymal cells 
(glioma). 
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6. MATERIALS AND METHODS. 
6.1. Cell culture and cell transfection.  
The human Glioblastoma cell line SF268 and U251MG were cultured in RPMI 1640 
medium (SIGMA) supplemented with 10% Fetal Bovine Serum (FBS) at 37 °C under 5% 
CO2 atmosphere. The human Colon Cancer Cell line HCT116 (Duke’s D), its isogenic 
derivate HCT116 p53 +/+ and LS180 (Duke’s B) were cultured in RPMI 1640 medium 
(SIGMA) and DMEM supplemented with 10% Fetal Bovine Serum (FBS) at 37 °C under 5% 
CO2 atmosphere. Primary cultures were maintained in F-10 medium (SIGMA N6908) 
supplemented with 20% FBS. For DNA transfection, SF268 and U251MG were transfected 
with Mirus TransIT-X2 Dynamic Delivery System (Mirus MIR6000) in exponential phase with 
2.5 µg of a small hairping RNA (shRNA) against NAMPT (QIAGEN SureSilencing shRNA 
insert sequence: 5’-AAGATCCTGTTCCAGGCTATT-3’), 2.5 µg of DNA carrying a pCMV-
Hygromycin B empty vector (QIAGEN non-coding sequence: 5’-
GGAATCTCATTCGATGCATAC-3’) and 2.5 µg of DNA of pCMV-Hygromycin B carrying a 
cDNA of NAMPT gene (SinoBiological HG10990-M; NCBI RefSeq: NM_005746.2).  
 
Table 1. Summary table including the commercial cell lines used and their characteristics. ATCC is the 
American Type Culture Collection. All cell lines are derived from human tumors. All cell lines are adherent-
type. 
Cell Line Tumor Grading Media Origin 
TP53 (+/+) 
HCT116 
Colorectal 
carcinoma 
Duke’s D RPMI 1640 + 
10% FBS 
ATCC 
TP53 (+/+) 
HCT116 
Colorectal 
carcinoma 
Duke’s D RPMI 1640 + 
10% FBS 
IBIS 
LS180 Colorectal 
carcinoma 
Duke’s B DMEM + NEAA ATCC 
SF268 Glioma Glioblastoma 
(Glioma IV) 
RPMI 1640 + 
10% FBS 
IBIS 
U251MG Glioma Glioblastoma 
(Glioma IV) 
RPMI 1640 + 
10% FBS 
IBIS 
 
6.2. Dissociation of Cancer Cells from Primary Tissue.  
Glioblastoma tumor samples were obtained from recent surgical resections in 
accordance with Hospital Virgen del Rocio (Tumor Biobank). Tumor samples were 
dissociated by enzymatic digestions to form a single cell suspension using Trypsin 2.5% 
10X (Invitrogen 15090046) and a collagenase type IV-DMEM solution (SIGMA C1889). 
After this, Glioblastoma cells were maintained in F-10 medium (SIGMA N6908) 
supplemented with 20% FBS at 37 °C under 5% CO2 atmosphere. 
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The following table summarizes the primary cell cultures generated by either primary 
tumor directly resected by the patient or primary tumor established by prior PDX 
(Patient derived Xenograft) amplification in mice by our laboratory [181] 
 
Table 2. Summary table including the parimary cell lines established and their characteristics. Molecular 
Diagnostics meet World Health Organization (WHO) 2016 classification. All cell lines are derived from human 
tumors. All cell lines are cultured in F-10 + 20% FBS media. 
 
Cell Line Tumor Molecular Diagnostics Origin 
G002 Glioma Glioblastoma, IDH-
wildetype 
Processed directly from 
human tumor fresh 
sample 
G003 Glioma Glioblastoma, NOS Processed directly from 
human tumor fresh 
sample 
G004 Glioma Glioblastoma, 
IDHwildtype 
Processed directly from 
human tumor fresh 
sample 
G005 Glioma Anaplastic 
Astrocytoma, NOS 
Processed directly from 
human tumor fresh 
sample 
G006 Glioma Glioblastoma, IDH-
wildtype 
Processed directly from 
human tumor fresh 
sample 
FA Colorectal 
carcinoma 
Neuroendocrine 
Colorectalcarcinoma 
Carnero’s lab 
(Processed from PDX) 
C-37 Colorectal 
carcinoma 
Colorectal carcinoma 
Liver metastase 
Carnero’s lab 
(Processed from PDX) 
C-22 Colorectal 
carcinoma 
Colorectal carcinoma 
Liver metastase 
Carnero’s lab 
(Processed from PDX) 
CE Colorectal 
carcinoma 
Colorectal carcinoma 
Liver metastase 
Carnero’s lab 
(Processed from PDX) 
 
6.3. Proliferation assay.  
A time course curve of parental (empty vector transfected cells) and NAMPT both 
cDNA and shRNA-expressing cells was generated by seeding 103 cells in 2.2 cm bottom-
well diameter dishes in triplicate samples. After 24 h, medium was changed (day 0) and 
the indicated culture media added. Every 24 hours, cells were fixed and stained with 
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crystal violet 1% (SIGMA C6158-50G). After extensive washing, crystal violet was 
solubilized in 20% acetic acid (Sigma) and quantified at 595 nm absorbance as a 
relative measure of cell number (BIORAD iMarkTM Microplate Reader). Values are 
expressed as the percentage of cell growth of cells growing in the presence of 10% FBS. 
Zero percent refers to the number of cells at day 0.  
 
6.4. Cytotoxicity assay.  
For the assay, 5x103 cells were seeded and then treated with the different compound 
at 11 different concentrations at 1/3 dilutions after 24 hours. Then, 96 hours later, cell 
viability was measured via MTT assay and validated independently by crystal violet 
staining as previously described [182]. IC50 was calculated as the concentration 
allowing 50% survival compared to day 0 controls. 
 
6.5. Colony formation assay and clonal heterogeinity analysis.  
103 cells were seeded in 10 cm plates, every condition in triplicate. The medium was 
replaced every 3 days and after 12 days the colonies were fixed and stained with a 
Crystal violet assay. After extensive-washing, colonies were counted. Values are 
expressed in number of observed colonies among 103 seeded cells. To analyze the 
clonal heterogeneity, 102 random colonies were classified in triplicate depending on its 
phenotype: Holoclone, Meroclone and Paraclone [183]. 
 
6.6. Sphere-forming assay.  
A total of 5x103 cells/mL/well were seeded in Ultra-low Attachment Plates containing 
MammoCultTM Basal Medium (Human) (Stem Cell Tech) supplied with 0.48 mg/mL 
hydrocortisone, 0.2% heparin solution and 10% MammoCultTM Proliferation Supplement 
(Human). After 4 days, primary tumorspheres were measured, both in size and in 
number, using an inverted microscope (Olympus CKX41).  
 
6.7. Single cell Sphere-forming assay.  
Single cells were individually seeded through cell sorting (BD FACS Jazz) in 96 well Ultra-
low attachment plates containing MammoCultTM Basal medium (Human) (Stem Cell 
Tech) supplied with hydrocortisone 0.48 mg/mL, Heparin solution 0.2% and 10% 
MammoCult™ Proliferation Supplement (Human). After 21 days, primary tumorspheres 
formed were measured both in size and number using inverted microscope (Olympus 
CKX41).  
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6.8. Fluorescence-activated cell sorting (FAC).  
 For flow cytometry analysis, the cell lines were harvested wit 0.25% trypsin, 0.02% EDTA 
(Sigma Aldrich). The cells were resuspended in cell culture media and were then 
counted and washed in PBS with 2% FCS and 5 mM EDTA and collected by 
centrifugation. The cells were blocked with FcR-Blocking reagent human (Miltenyi 
Biotec) for 10 min on ice. Afterwards, the cells were stained with CD133/1-PE (Miltenyi 
Biotec) or CD44 (AC-CD44-PE, Miltenyi) at 4°C for 30 min in the dark. Following antibody 
labeling, the cells were washed twice with PBS with 2% FCS and 5 mM EDTA. Finally, the 
cells were resuspended in PBS with 2% FCS and 5 mM EDTA. Data were acquired on a 
FACSCanto II (BD Biosciences, San Jose, USA) and analyzed with Diva-BD software. 
 
6.9. Quantitative RT-PCR.  
Total cellular RNA was isolated with the RNeasy kit (Qiagen) and reversed transcribed 
into cDNA using 2.0 µg of RNA, random primers, dNTP mix and a Multiscribe Reverse 
Transcriptase in a total volume of 50 µL (High Capacity Transcription Kit-Applied 
Biosystems).  
 
Table 3. Probe sets used for qRT-PCR analysis. Probe names, amplicon lengths, provider and reference IDs of 
the probes used in this thesis 
Probe Amplicon Length Provider Reference 
NAMPT 80 Thermofisher Hs00237184_m1 
SIRT1 91 Thermofisher Hs01009006_m1 
GAPDH 58 Thermofisher Hs03929097_g1 
SNAI1 66 Thermofisher Hs00195591_m1 
TWIST1 85 Thermofisher Hs01675818_s1 
FOXC2 102 Thermofisher Hs00270951_s1 
VIM 73 Thermofisher Hs00185584_m1 
NANOG 99 Thermofisher Hs04260366_g1 
SOX2 91 Thermofisher Hs01053049_s1 
OCT4 77 Thermofisher Hs00999632_g1 
SERPINE1 84 Thermofisher Hs00167155_m1 
CD133 80 Thermofisher Hs01009257_m1 
ABCC3 64 Thermofisher Hs00978452_m1 
JUN 91 Thermofisher Hs01103582_s1 
TEAD4 125 Thermofisher Hs01125032_m1 
CSNK1A1 130 Thermofisher Hs00793391_m1 
HES1 78 Thermofisher Hs00172878_m1 
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Real time PCR was performed on an Applied Biosystem 7900HT cycler using gene-
specific probes from Life technologies as follows: GADPH was used as housekeeping. 
Relative quantitation values were expressed as 2-ÄCt or relative mRNA expression.  
 
6.10. Immunoblotting.  
Cells were were lysed in RIPA buffer (Tris–HCl pH 8.0 25 mM, NaCl 150 mM, NP40 1%, 
Sodium desoxycholate 1%, SDS 1%, Na3VO4 1 mM, EDTA 0.5 M, complete protease and 
phosphatase inhibitor cocktail, 2 mM) and then subjected to 3 sonication cycles during 
5 seconds. The amount of protein was determined by Bradford assay using BSA (bovine 
serum albumin) as a standard. The primary antibodies were purchased from 
commercial sources as follows:  á-tubulin 1:10000 (SIGMA – T9026), NANOG (ab80892 
Rabbit polyclonal, Abcam); NAMPT (Anti-Visfatin antibody BETHYL A300-779A). The 
secondary antibodies used were: Goat pAB to Rabbit IgG (HRP) 1:5000 (ABCAM 
ab97051), Rabbit pAB to Mouse IgG (HRP) 1:5000 (ABCAM ab97046). A complete list the 
antibodies used and their dilutions is shown in Table 4. 
 
Table 4. Antibodies characteristics. List of used antibodies and their usage. WB – Western Blot; IH – 
Immunohistochemistry; FC – Flow cytometry 
 
Antibody 
 
Molecular weight (kDa) 
 
Provider 
Function 
WB IH FC 
NAMPT 
(A300-779A) 
54 Bethyl 1:1000   
NAMPT 
(A300-372A) 
54 Bethyl  1:1000  
α-tubulin 
(T9026) 
55 SIGMA 1:10000   
NANOG 
(ab80892) 
42 Abcam  1:500  
CD133 
(CD133/1-PE) 
133 Miltenyi   1:25 
CD44 
(AC-CD44-PE) 
75 Miltenyi   1:25 
Rabbit pAB to Mouse 
(ab97046) 
 Abcam 1:4000   
Goat pAB to Rabbit 
(ab97051)  
 Abcam 1:5000   
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6.11. Immunohistochemistry.  
Paraffin blocks were cutted into 2.5ìm sections, mounted and dried on glass slides. 
Sectioned tissues were deparaffinized in xylol, followed by dehydration in graded 
alcohol solutions and were stained with hematoxylin-eosin (H&E). Epitope antigen 
retrieval was performed in sodium citrate (pH 6.5). Endogenous peroxidase activity was 
blocked using DAKO blocking solution for 20 minutes at room temperature. Non specific 
protein binding was saturated using PBS+10% FBS, 1% BSA and 0.3% Triton X-100 for 1h at 
room temperature. The primary antibodies (NANOG abcam ab80892; NAMPT Bethyl 
A300-372A) were incubated overnight at 4ºC. A secondary antibody anti-goat 
(ab97100) was applied for 1h at room temperature, and the immunocomplexes were 
revealed using substrate buffer and chromogen (Envision, Flex DAKO). The tissues were 
counterstained with hematoxylin (DAKO), rehydrated in a graded alcohol series, and 
mounted using coverslips. 
 
A complete list the antibodies used and their dilutions is shown in Table 4. 
 
6.12. Migration assay.  
2.25 x 104 cells/well were seeded in serum free media in a CytoSelectTM 24-Well Cell 
Invasion Assay (Boyden chamber) (CELL BIOLABS CBA-110). 500 µL of RPMI 1640 
supplied with 10% FBS and 2% FBS were added to the lower well of the invasion 
chamber in different experiments and incubated at 37 °C under a 5% CO2 atmosphere . 
After 24 and 48 hours post-seeding, the bottom of each well of the chamber were 
swabbed with swabs to remove non-migratory cells. To measure the amount of cells 
which were able to migrate, we transferred each insert in a clean well containing 400 
µL of a Cell Stain Solution, solubilized with the extraction solution provided by the kit and 
measured at 595 nm. 
 
6.13. Soft-Agar assay.  
To measure the anchorage-independent growth, 2x104 cells were suspended in 1.4% 
agarose D-1 Low EEO (Pronadisa) growth medium containing 10% FBS, disposed onto a 
solidified base of growth medium containing 2.8% agar (agarose D-1 Low EEO, 
Pronadisa) and overlaid with 1 ml of growth medium. After 24 h, media containing 10% 
FBS were added to each 35 mm dish and renewed twice weekly. Colonies were 
measured both in colony size and number after 3 weeks using an inverted microscope 
(OLYMPUS CKX41) with an integrated camera (OLYMPUS SC30, U-CMAD3) and phase 
contrast slider model OLYMPUS IX2-SLP. Provided pictures were taken with the same 
inverted microscope. All the conditions were performed in triplicate. Culture media 
tested were as follows: RPMI 1640 10% (Supplemented with 10% FBS), RPMI 1640 2% 
 
 
35 
(Supplemented with 2% FBS), RPMI 1640 10% + 60 ng/mL Human Visfatin protein, RPMI 
1640 10% + 1 mM NMN. 
 
6.14. Xenograft in nude mice.  
Tumorigenicity was assayed by the subcutaneous injection of 1x106 cells into the back 
legs of 4-week-old female athymic nude mice. Animals were examined twice a week 
and incubated for 8 weeks. Tumors were measured using calipers. Tumor volume (mm3) 
was determined by using the volume formula. All animal experiments were done under 
the experimental protocol approved by Institute of Biomedicine of Sevilla (IBiS) 
Institutional Committee for Care and Use of Animals. Regarding ethics, maintenance 
and procedures of the animal, everything have been performed according to the 
ARRIVE guidelines in order to preserve by far the replacement, refinement and 
reduction of Animals in Research. 
 
6.15. Tumor-driven CIC amplification assay in nude mice.  
Tumor initiation  by CIC was assayed by the subcutaneous injection of a low number of 
CIC cells (7500), previously cultured either by tumorspheres or sorted by CD133+ cells 
into the back legs of 4-week-old female athymic nude mice. Animals were examined 
twice a week and incubated for time enough until we saw the tumor. Tumors were 
measured using calipers. 
 
6.16. Bioinformatic Analysis. 
 
The analyzed databases have been obtained and downloaded from the Atlas of the 
Genome of Cancer (TCGA) and Genetic Expression Omnibus (GEO), which are part of 
the National Center for Biotechnology Information (NCBI), a part of the Library National 
Medicine of the United States. GEO is an international public database and repository 
that contains free distribution files of experimental microarray data, new generation 
sequencing and other high performance functional genomics data submitted by the 
scientific community. GEO has three types of files: 
 
• Parental analysis platforms (GPL files) where you can find the identifiers of each probe 
used. 
• Series of experimental collections (GSE Archives) 
• Lists of databases (GDS files). 
 
Each of these files is assigned an assigned name followed by the model organism from 
which the biological sample comes. Array analyzes were performed under microarray 
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processing and analysis programs of the 'Bioconductor' package, operated under the 
computer programming language 'R'. The analysis tools incorporate features of other 
Bioconductor packages as indicated in the Table 5. 
 
6.16.1. Retrospective Analysis of NAMPT Gene Expression in Human Gliomas.  
Correlations between glioma grade, patient survival, tumor recurrence and NAMPT 
gene expression were determined through analysis of French, TGCA, French-Core Exon, 
Sun Brain and Freije datasets respectively which are available through Oncomine 
(Compendia Biosciences, www.oncomine.org) and R2: Genomics analysis and 
visualization platform (http://r2.amc.nl/ ). High and low groups were defined as above 
and below the mean respectively. For analysis with high and low groups, high was 
defined as greater than one standard deviation above the mean, low is greater than 
one standard deviation below the mean. The National Cancer Institute’s Repository for 
Molecular Brain Neoplasia Data (REMBRANDT, http://rembrandt.nci.nih.gov ) was also 
evaluated for correlations between glioma patient survival and gene expression with 
up- or downregulation being defined as a 2 fold change relative to mean values. 
 
All grouped data are presented as mean ± standard error. Difference between groups 
was assessed by ANOVA or Student’s t-test using GraphPad Prism software. For survival 
analysis, Kapalan Meier curves were generated using Prism software and R2 Kaplan 
Meier plotting service and log Rank analysis performed. All experiments were repeated 
in each condition in at least duplicate with triplicate technical replicates. Data 
distribution was assumed to be normal but this was not formally tested. Data obtained 
for retrospective analysis were collected and processed in appropriate experimental 
arms. 
 
6.16.2. Retrospective Analysis of NAMPT Gene Expression in Human Colon Tumors.  
Correlations were determined through analysis of GSE20916, GSE10950, GSE18105, 
GSE8671, GSE4183, GSE17538, GSE34053 and GSE14773 respectively which are available 
through Oncomine (Compendia Biosciences, www.oncomine.org) and R2: Genomics 
analysis and visualization platform (http://r2.amc.nl/ ). High and low groups were 
defined as above and below the mean respectively. For analysis with high and low 
groups, high was defined as greater than one standard deviation above the mean, low 
is greater than one standard deviation below the mean.  
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Table 5. Bioconductor packages used for Bioinformatic Analysis. Package names and functions are provided. 
All the commands were operated under the computer programming language 'R'. 
Package Name Function 
Geo Query Allows to download microarray sets from 
the GEO repository. 
AFFY Tool containing functions for the analysis 
of oligonucleotide microarray data 
(Affymetrix). 
AFFYPLM Extends and enhances the functionality of 
the AFFY package with quality analysis 
tools. 
GENEFILTER It provides functions for filtering genes 
from a set of microarrays. 
LIMMA Tool for the analysis of differential 
expression in microarrays 
hgu133plus2 Annotation packet. It indicates the 
correspondence between the probes 
and the gene it represents, among other 
types of annotation information: GO 
Terms, Entrez IDs, chromosome, etc. 
KEGGREST Package that provides an interface with 
the KEGG REST server. 
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7. RESULTS 
7.1. GLIOMAS 
 
7.1.1. NAMPT correlates with glioma tumor clinical outcomes. 
 
To confirm the clinical significance of NAMPT expression in brain tumors, we analyzed 
public available ectoderm-derived tumor datasets for NAMPT levels (Figure 7A). We 
determined that gliomas, pilocytic astrocytomas but not in neuroblastomas express 
more NAMPT than healthy human brain tissue. We found that NAMPT was highly 
overexpressed in glioblastoma tissue compared with healthy brain tissue in different 
databases (Figure 7B). This correlation was also observed in an mRNA pool of nine 
different glioma cell lines (Figure 7C), as well as in astrocytoma, glioma grade III, and 
glioblastoma, glioma grade IV tumors (Figure 7C).  
 
Figure 7. NAMPT expression correlates with tumor grade. (A) Analysis of Normal Brain (N) [n=216], Glioma (Gli) 
[n=577], Pilocytic Astrocytoma (PA) [n=41] and Neuroblastoma (Nb) [n=45] datasets available through the R2 
database for NAMPT expression (B) Analysis of Normal Brain [n=23] and Glioblastoma [n=81] datasets from the 
Sun database available in Oncomine for NAMPT expression (C) New retrospective analyses of new databases, 
comparing Normal Brain [GSE13564, GSE11882] [n=216], Glioblastoma [GSE4290, GSE16011 - Glioblastoma 
series taken together; n=159], Anaplastic Astrocytoma (AA) [GSE4290, Astrocytoma grade III - GSM series; 
n=16] and Glioblastoma primary cell lines (GBM) [n=9; GSM379855, GSM379856, GSM379857, GSM379858, 
GSM379870, GSM379871, GSM379872, GSM379873 and GSM379874] for NAMPT expression (D) Analysis of the 
Oncomine Glioma dataset stratifying NAMPT according to Glioma grade: Grade II [n=45] Grade III [n=31] and 
grade IV [n=81] tumors (E) A second database analyzed in Oncomine for NAMPT expression correlating with 
tumor grade: Grade II [n=50], Grade III [n=26], Grade IV [n=77] (F) Analysis of TCGA Glioblastoma molecular 
subtypes Proneural, Neural, Classical and Mesenchymal. Statistics [*, p< 0.05; **, p< 0.01; ***, p< 0.001 with 
ANOVA compared to Normal brain in (A, B, C) and Grade II (II) in (D, E) 
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Furthermore, NAMPT expression was strongly correlated with tumor grade in two 
independent datasets (Figure 7D-E), indicating that NAMPT is highly overexpressed in 
human brain tumors and correlates with tumor stage. According to the TCGA 
molecular classification of glioblastoma, we found that NAMPT is particularly expressed 
in the classical and mesenchymal subtype (Figure 7F). 
 
Figure 8. Patient survival according to NAMPT expression and Glioma grade.  
Analysis of Kaplan-meier curves in glioma datasets according to NAMPT expression available through 
Oncomine and R2: GSE16011 (A) [n=124 NAMPT low; n=149 NAMPT high; p< 0.001 with log-rank analysis]; 
GSE43378 (B) [n=31 NAMPT low; n=19 NAMPT high; p< 0.001 with log-rank analysis]; GSE26576 (C) [n=13 NAMPT 
low; n=34 NAMPT high; p=0.054 with log-rank analysis]; GSE16011, subtype grade II. (D) [n=9 NAMPT low; n=15 
NAMPT high; p= 0.172 with log-rank analysis]; GSE16011, subtype grade III. (E) [n=40 NAMPT low; n=45 NAMPT 
high; p< 0.0001 with log-rank analysis]; and GSE16011, subtype grade IV. (F) [n=85 NAMPT low; n=71 NAMPT 
high; p< 0.001 with log-rank analysis], TCGA 540 glioblastoma dataset [n=96 NAMPT low; n=408 NAMPT high; 
p< 0.0001 with log-rank analysis] (G), TCGA 395 glioblastoma dataset [n=68 NAMPT low; n=309 NAMPT high; 
p< 0.001 with log-rank analysis] (H) and French Exon-Core dataset [n=85 NAMPT low; n=10 NAMPT high; p< 
0.001 with log-rank analysis] (I). 
 
To further evaluate the potential correlation between NAMPT expression and patient 
outcome, we generated Kaplan-Meier survival curves from several public databases 
(Figure 8). In all datasets analyzed, high NAMPT expression was indicative of poor 
survival (Figure 8A-C). Because NAMPT is closely associated with tumor stage, we 
segregated patients by tumor grade to determine whether the effects of the enzyme 
on survival were stage-related or stage-independent. NAMPT correlated with poor 
 
 
43 
prognosis independently of tumor grade in all datasets (Figure 8D-F). We also found 
that glioblastoma grade IV tumors expressing high levels of NAMPT had a worse 
prognosis (Figure 8G), which was confirmed in other datasets (Figure 8H-I).  
Altogether, these data demonstrate that NAMPT expression in gliomas is an 
independent indicator of poor patient outcomes, which may indicate that NAMPT has 
an important oncogenic function in glioma cells.  
 
7.1.2. NAMPT strengthens tumorigenic properties enriching cancer initiating cell 
phenotype 
 
To elucidate the causal role of NAMPT, we studied whether NAMPT promotes 
tumorigenicity in glioma cells. We ectopically expressed NAMPT cDNA (Isoform A) in the 
human glioblastoma cell lines SF268 and U251MG, then selected transfectants to 
create a stable transfection pool (NAMPT) (Figure 9A-D). As proof of concept, we also 
counteracted endogenous NAMPT gene expression by expressing a small hairpin RNA 
against NAMPT (sh), producing a daughter cell line expressing reduced levels of the 
enzyme (Figure 9C-D). We then compared the behavior of the parental cell line 
(expressing only vector, V) with that of isogenic daughter cells exhibiting NAMPT 
overexpression (NAMPT) or NAMPT underexpression (sh). The NAMPT-overexpressing cells 
grew faster than the parental cells, indicating that NAMPT confers a proliferative 
advantage (Figure 9E-F), while the NAMPT-underexpressing cells grew slower than the 
parental cells, confirming the role of NAMPT in tumor proliferation. The NAMPT-
overexpressing cells also overcame apoptosis when clonogenic assays were performed 
at low cell densities (Figure 9G-H), while the NAMPT-underexpressing cells formed 
reduced numbers of colonies compared with the parental cells (Figure 9G-H).  
NAMPT overexpression strongly correlated with poor patient prognoses (Figure 2). It has 
been proposed that CICs are primarily responsible for tumor relapses and poor 
therapeutic responses, as CICs are able to reconstitute entire tumors.  
Therefore, we tested the ability of cells with different levels of NAMPT expression to form 
tumorspheres, a functional assay for the cancer stem-like phenotype [171-174]. The cells 
were seeded and visualized five days later. The parental cells formed spheres at this 
stage, which were considered 1st generation tumorspheres. The number of 
tumorspheres derived from the cells with increased NAMPT expression was significantly 
higher than that derived from the control cells (Figure 9I), while the cells with decreased 
NAMPT expression showed a clear reduction in the number of tumorspheres (Figure 9I). 
To further explore the cancer-initiating cell properties induced by NAMPT, we cultured 
cells at low densities to form independent colonies comprising individual clones, which 
were previously classified as holoclones, meroclones and paraclones based on their 
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ability to reconstitute tumors from a single cell [171-174]. Holoclones are believed to be 
derived from stem cells, while paraclones are differentiated cells that are incapable of 
reconstituting a culture [183]. Meroclones are intermediate phenotypes between holo- 
and paraclones. The percentage of holoclones in NAMPT-expressing cells was 
increased from 20% to 60% in SF268 (Figure 9J-K) and from 60% to 80% in U251MG, while 
the percentage of holoclones was decreased in cells expressing NAMPT shRNA (Figure 
9J-K), indicating a relationship between NAMPT and the CIC phenotype.  
 
Figure 9. Functional analysis and CIC-like properties in cells according to NAMPT expression 
(A, B) Q-RT-PCR shows NAMPT overexpression in either SF268 (A) or U251MG (B). (C, F) Western blot analysis 
shows NAMPT overexpression and NAMPT silencing with shRNA in SF268 (C) and U251MG (F). We now 
compare cell properties of cells expressing only a shRNA against NAMPT (sh, ☐, white bars) or NAMPT 
endogenous overexpression (NAMPT, , black bars) to parental expressing only vector (v, , grey bars) (D, E) 
Analysis of the growth curve [*, p<0.05; **, p<0.01 with ANOVA compared to vector]. (G, H) Clonogenicity 
assay for 1000 cells [**, p<0.01 with ANOVA compared to vector]. (I) Tumorsphere-forming assay for 3000 cells 
in both cell lines. (J, K) Analysis of clone phenotypes [holoclones – black, meroclones – gray, paraclones – 
white] [*, p< 0.05; **, p< 0.01 with ANOVA compared to vector]. (J) shows data from SF268 cell line. (K) shows 
data from U251MG cell line.  (L) CD133 analysis with FACS [*, p< 0.05; **, p< 0.01 with ANOVA compared to 
vector]. (M) CD44 analysis with FACS [*, p< 0.05; **, p< 0.01 with ANOVA compared to vector] 
 
In addition, FACS analysis of tumor cells showed higher stem cell phenotypic marker 
expression, which correlated with NAMPT expression. NAMPT-expressing cells showed 
increases in both CD133+ (Figure 9L) and CD44+ pools (Figure 9M). However, NAMPT-
underexpressing cells showed clear reductions in the CD133+ and CD44+ pools (Figure 
9L-M), confirming that NAMPT is a factor that facilitates tumor cell de- differentiation to 
a pluripotent-like state. A second shRNA against NAMPT showed similar results (Figure 
10). 
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To finally confirm these data, we tested the ability of cells with different levels of NAMPT 
expression to form tumorspheres from one isolated single cell, another functional assay  
 
Figure 10. FACS analysis relating CIC-like properties using a second shRNA against NAMPT. (A) Western blot 
analysis shows cells expressing only vector (vector) and a second shRNA against NAMPT (sh-2) in SF268 and 
U251MG. (B) We compare CD133 and CD44 fraction of cells expressing only a second shRNA against NAMPT 
(sh-2, , green bars for SF268 and , yellow bars for U251MG) or NAMPT endogenous overexpression (NAMPT, 
, black bars) to parental expressing only vector (v, , grey bars) [*, p< 0.05; **, p< 0.01; ***, p< 0.001 with 
ANOVA compared to vector] 
for the CIC-like phenotype [174, 184-186]. The cells were seeded at one cell per well 
and visualized 21 days later (Figure 11A). 
The parental cells formed spheres at this stage, which were considered 1st generation 
tumorspheres. The number and size of tumorspheres derived from the cells with 
increased NAMPT expression was significantly higher than that derived from the control 
and parental cells (Figure 11B-C).  
 
 
Figure 11. Single-cell sphere-forming assay. (A) Representative picture of spheres phenotype (B) Single cell 
tumorsphere forming efficiency percentage. (C) Single cell tumorsphere size. (D) Single cell colony (full 
culture) forming efficiency percentage. We compare cell properties of cells expressing NAMPT endogenous 
overexpression (NAMPT, , black bars) to parental expressing only vector (v, , grey bars), in (D) a shRNA 
against NAMPT (sh, ☐, white bars) is also included. [*, p< 0.05; **, p< 0.01 with ANOVA compared to vector 
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We also explored the effect of a second sh in both cell lines in order to avoid 
overlapping effects and we found similar results (Figure 12). 
 
 
Figure 12. Single-cell sphere-forming assay using a second shRNA against NAMPT. (A) We compare Single cell 
tumorsphere forming efficiency percentage of cells expressing only a second shRNA against NAMPT (sh-2, , 
green bars for SF268 and , yellow bars for U251MG) or NAMPT endogenous overexpression (NAMPT, , black 
bars) to parental expressing only vector (v, , grey bars)  
NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide 
(NMN), which is the rate-limiting step in the NAD+ salvage pathway. If the enzymatic 
activity of NAMPT is directly responsible for these phenotypes, the phenotype should be 
recovered by directly adding the product of the enzyme to cells. Therefore, we 
repeated the previous surrogate experiments and added saturating concentrations of 
NMN to cells expressing low levels of NAMPT (sh supplemented with NMN, sh+NMN). In 
these experiments, we rescued the parental phenotypes by supplying the cells with the 
NAMPT metabolic product NMN (Figure 13). In all cases, the cells with downregulated 
NAMPT expression but with abundant NMN in the media behaved similarly to the 
parental cells. However, they did not exhibit the increased levels of tumorigenicity 
induced by NAMPT overexpression (Figure 13).  Similar results were found using a 
second shRNA against NAMPT (Figure 14). 
 
NAMPT is also known to act as an extracellular soluble protein named visfatin, which 
has activity that is not related to the enzymatic activity of the protein [187, 188]. 
Therefore, we explored the effects of extracellular visfatin supplementation in NAMPT- 
underexpressing cells and found that the NAMPT-underexpressing cells were rescued, 
similar to the above findings (Figure 13). However, as before, the cells did not exhibit the 
increased levels of tumorigenicity induced by NAMPT overexpression (Figure 13). Similar 
results were found using a second shRNA against NAMPT (Figure 14). 
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Figure 13. Effect of the addition of the NAMPT product NMN and Visfatin (eNAMPT) 
We added 1 mM NMN and 60 ng/mL of Visfatin to cells expressing the shRNA against NAMPT (sh+N, , blue 
bars; sh+V, , red bars) and compared different properties to shRNA only (sh, ☐, white bars)  (A) growth curve 
for SF268 (B) growth curve for U251MG (C) Clonogenicity in SF268 (D) Clonogenicity in U251MG (E) Analysis of 
clone phenotypes in SF268 [holoclones – black, meroclones – gray, paraclones – white] (F) Analysis of clone 
phenotypes in U251MG (G) CD133 analysis for both cell lines using NMN (H) CD133 analysis of both cell lines 
using Visfatin (I) CD44 analysis for both cell lines using NMN (J) CD44 analysis for both cell lines using Visfatin (K) 
Tumorspheres assay for SF268 (L) tumorsphere assay for U251MG [*, p< 0.05; **, p< 0.01; ***, p< 0.001 
compared to sh].  
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These results clearly indicate that NAMPT gene overexpression provides the protein with 
properties beyond those associated with its enzymatic function in the salvage pathway, 
conferring CIC-like properties to the cells in which is expressed. 
 
 
Figure 14. CD133 and CD44 analysis using a second shRNA against NAMPT. (A) We compare CD133 
percentage of cells expressing only a second shRNA supplied with NMN (sh-2 + NMN, , green-blue bars for 
SF268 and, sh-2 + NMN, , yellow-blue bars for U251MG) and Visfatin (sh-2 + V, , brown bars for SF268 and, 
sh-2 + V, , orange bars for U251MG) to a second shRNA against NAMPT (sh-2, , green bars for SF268; , 
yellow bars for U251MG) and (B) CD44 percentage [*, p< 0.05; **, p< 0.01; compared to sh-2].  
 
7.1.3. NAMPT expression correlated with high levels of cancer initiating cell-like cells in 
glioblastoma directly from patients. 
 
To approach our findings to a more in vivo situation, we first took 14 glioblastoma tumor 
samples directly from patients as well as matched non-tumor samples. In these samples 
we measured the expression of NAMPT and Nanog, as surrogated marker of CIC-like 
levels of these tumors (Figure 15A). We found a clear increase of NAMPT and Nanog in 
tumoral vs non-tumoral samples (Figure 15B and 15C). And more importantly, there was 
a clear correlation (pearson r=0.53, p<0.01) between the expression of Nanog and 
NAMPT (Figure 15D). These data reinforce the direct relationship between NAMPT and 
the cancer stem cell like component of glioblastoma tumors. 
Then, we took 5 fresh glioblastoma samples from patients (Table 6). After tissue 
disaggregation, we directly measured NAMPT levels by Q-RT-PCR and in parallel 
seeded 3000 cells to measure the number of tumorspheres formed (Figure 15E). Then 
we plotted to establish 1 to 1 correlation, between the level of NAMPT and the number 
of tumorspheres. We found a strong direct correlation of the tumorsphere number and 
NAMPT levels for each tumor (Figure 15E, pearson r=0.709; p<0,01).  
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All these data strongly confirm that NAMPT levels correlates with the activation of the 
cancer stem cell–like phenotype in human glioblastoma tumors.  
 
Table 6. Glioblastoma samples from patients. Sample ID and Molecular diagnosis (WHO 2016) are shown 
 
 
Figure 15. Analysis for NAMPT expression and CIC-like markers in paired samples of a Human Tissue 
microarray (TMA). (A) Fourteen glioblastoma tumor samples with paired normal tissue were processed as a 
TMA. TMAs were stained for NAMPT and Nanog according to M&M. In these samples we evaluated the 
expression of NAMPT and Nanog, as surrogated marker of cancer stem cell-like levels of these tumors. (B) 
Levels of NAMPT and (C) Nanog were related in matched samples, from the same patient. (D) Evaluation of 
the correlation between matched samples of NAMPT and Nanog. (Pearson R= 0.5349, p< 0.01) (E) Five fresh 
glioblastoma samples from patients were processed for functional assays. After tissue disaggregation, we 
directly measured NAMPT levels by Q-RT-PCR and seeded 3000 cells in parallel to measure the number of 
tumorspheres formed. Then we plotted to establish 1 to 1 correlation, between the level of NAMPT and the 
number of tumorspheres. (Pearson R= 0.7096, p< 0.01) 
 
 
Sample Molecular diagnosis (WHO 2016) 
 
G002 
 
Glioblastoma Grade IV IDH1-wild type 
G003 Glioblastoma Grade IV NOS 
G004 Glioblastoma Grade IV IDH1-wild type 
G005 Anaplastic Astrocytoma Grade III NOS 
G006 Glioblastoma Grade IV IDH1-wild type 
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7.1.4. NAMPT induces pluripotency via signalling pathways controlling stemness. 
 
To support this novel finding, we decided to explore the correlation between NAMPT 
expression and cell stemness transcription.  
 
Figure 16. Transcriptional analysis of EMT and Stem Pathway Effectors according to NAMPT levels. (A) Q-RT-
PCR analysis of NAMPT overexpression in empty vector [**, p < 0.01 with t-test]. Q-RT-PCR analysis of stem cell 
gene expression in empty vector: NANOG [***, p < 0.001 with t-test], SOX2 [*, p < 0.05; **, p < 0.01 with t-test], 
OCT4 [**, p < 0.01; ***, p < 0.001 with t-test] and CD133 [*, p < 0.05; ** p < 0.01 with t-test]. (B) RT-qPCR analysis 
of EMT gene expression in empty vector: FOXC2 [**, p < 0.01 with t-test], TWIST1 [*, p < 0.05; **, p <0.01 with t-
test], VIM [*, p <0.05; **, p <0.01 with t-test] and SNAI1 [**, p < 0.01 with t-test]. (C) Analysis of the Yamanaka 
dataset (GSM241846) with respect to induced pluripotent stem cell (iPSC) generation from human dermal 
fibroblasts (hDF) for NAMPT expression [*, p = 0.01; ** p < 0.01 with ANOVA compared to human dermal 
fibroblasts]. (D) Analysis of the Yamanaka dataset (GSE15148) with respect to iPSC generation from mouse 
embryonic fibroblasts (mEF) for NAMPT expression. Mouse embryonic stem cells (mESC) for NAMPT expression 
[*, p = 0.01; ** p < 0.01 with ANOVA compared to mouse embryonic fibroblasts]. (E) Analysis of the Thomson 
dataset (GSE5259) with respect to iPSC generation from human foreskin fibroblasts (parent) for NAMPT 
expression. Human embryonic stem cell lines (H1L and H7) transcriptional analysis for NAMPT expression [*, p = 
0.01; ** p < 0.01 with ANOVA compared to human foreskin fibroblasts]. We compare cell properties of cells 
expressing NAMPT endogenous overexpression (NAMPT, , black bars) to parental expressing only vector (v, 
, grey bars). 
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We analyzed whether the stem transcriptional core formed by SOX2, OCT4 and 
NANOG was altered by NAMPT levels. By Q-RT-PCR, we analyzed each transcript 
individually, confirmed the overexpression of NAMPT in SF268 and U251MG cells (Figure 
16A) and found that NAMPT-overexpressing cells significantly induced Sox2, Oct4 and 
Nanog mRNA expression (Figure 16A).  
Furthermore, these cells also showed increased levels of CD133 transcripts (Figure 16A).  
The epithelial-mesenchymal transition (EMT) is an essential step mediating tumor 
reprogramming and metastasis. Several genes are expressed during EMT induction [189] 
[190]. For the next step in our study, we tested whether NAMPT upregulated some of 
these steps. We found that NAMPT-overexpressing cells showed induction of FOXC2, 
TWIST1, VIM and SNAI1 expression (Figure 16B).  
 
 
Figure 17. NAMPT-driven Gene Signature involving pathways controlling CSC-like pathways (A) Heatmap 
analysis of the gene signature triggered by NAMPT associated to pathways controlling CSC-like properties in 
the Sun dataset (GSE4290) (B) Pathways controlling CIC-like properties related to NAMPT expression. (C) 
Genes associated to NAMPT gene expression [all p< 0.01, Pearson r is shown in each case], and the pathway 
each gene is associated to. (D) Overall survival probability comparing the patients showing low expression 
signature of selected genes vs high expression signature. R2 expression analysis of the gene signature 
triggered by NAMPT in the Sun Brain tumor database in a biased cohort of patients with high signature 
expression [n=10] and low signature expression [n=10] shows poor survival in patients [p=0.06 with log-rank 
analysis]. (E) Analysis of the expression of the different genes selected of the signature in SF268 and U2521MG 
expressing NAMPT. 
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Then, we analyzed iPSC transcriptional databases. We found that NAMPT is highly 
overexpressed in iPSCs and embryonic stem cells (Figure 16C-E), as they maintain a 
pluripotent, self-renewed state. 
 
Figure 18. Analysis of NAMPT-related signature in the TCGA database. 
(A) NAMPT-derived signature is represented. (B). Relative expression levels of each gene are represented in 
normal brain vs glioma samples. (C) NAMPT-derived signature levels classify Grade IV gliobastoma samples. 
(D) NAMPT-derived signature levels classify the different subtypes of Glioblastoma according to the whole 
dataset of Glioblastoma TCGA dataset. (E-F) Overall survival probability comparing the patients showing low 
expression signature vs high expression signature. R2 expression analysis of the gene signature triggered by 
NAMPT in the TCGA 540 (E) or French (F) glioblastomma databases in a biased cohort of patients with high 
signature expression [n=10] and low signature expression [n=10] shows poor survival in patients [p<0.01 with 
log-rank analysis]. 
 
With the aim of identifying the pathways that induce cell stemness and pluripotency, 
we correlated NAMPT expression with stem cell pathways in several in silico glioma 
retrospective studies (GSE16011, GSE4290, GSE4271, GSE43378, and GSE7696). We found 
a positive correlation with the different stem cell signaling pathways. NAMPT expression 
showed a strong correlation (pearson r) with Hippo, Wnt, Hedgehog and Notch, as well 
as ABC transporters as markers of stem functionality (Figures 17A-C). Furthermore, 
NAMPT also showed correlation to OSKM reprogramming factors (Figure 17C). The 
analisis of the geneset comprising all these genes that correlate to NAMPT is highly 
predictive of patient prognosis (Figure 17D). Therefore, we set to determine whether the 
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different pathways were hyperactivated in NAMPT-overexpressing cells. To this end, we 
used Q-RT-PCR to measure individually the mRNA levels for Nampt, CD44, Jun, TEAD4, 
CSNK1A1, ABCC3, Serpine1 and HES1, as the transcriptional markers of the CSC 
pathways (From Figure 17).  
 
Figure 19. Analysis of NAMPT-related signature in GSE16011 database. Heatmap of NAMPTdriven signature in 
Grade IV Glioma only in GSE16011 database 
 
We observed clear transcriptional activation of all these genes in our cells 
overexpressing NAMPT (Figure 17E). It appears that NAMPT overexpression activates 
stem cell signaling, eventually activating Hippo, Hedgehog, Wnt and Notch as effectors, 
contributing to cell stemness.  
 
7.1.5. NAMPT triggers a gene signature that correlates with poor survival in glioma 
 
NAMPT induces genes associated with the EMT, the Notch pathway and iPSCs, which 
increase tumorigenicity and expression of the CIC-like phenotype. It is possible that 
these factors can be used to predict the prognosis of glioma patients. We selected 
NAMPT and genes activated by its overexpression, including Jun, CD44, HES1, TEAD4, 
CSNK1A1, ABCC3 and Serpine1 (Figure 18A). All these transcripts were increased in 
glioblastoma patient tissue samples compared to their corresponding levels in normal 
brain tissue (Figure 18B). This signature is able to stratify patients with grade IV 
glioblastoma (Figure 18C). Interestingly, this signature also stratifies patients with 
different glioblastoma subtypes according to TCGA database, showing higher 
expression among mesenchimal subtypes, and lower among the proneural subtypes 
(Figure 18D). The application of the signature clearly distinguishes the patients with 
good from bad pronosis in the databases applied (Figures 18E-F). 
 
Through the analysis of the NAMPT-derived signature in different datasets, we observed 
that the incidence of the gene signature was driven by grade in brain tumor patients 
(Figure 18C-D and Figure 19). 
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The percentage of patients who showed a clear positive NAMPT-derived signature 
increased along with tumor grade in the different datasets analyzed (Figures 20-22), 
exceeding 50% among patients with grade IV tumors.  
 
Figure 20. GSE16011 grade stratification according to signature correlation. Individual stratification of the 
gene dataset according to NAMPT expression and its correlation with the other elements of the gene 
signature. 
 
Furthermore, comparisons of Heat map plots between the groups with grade III and IV 
tumors with high expression of the signature and the groups with grade IIII and IV tumors 
with low expression of the signature showed that patients with a positive signature have 
a poor prognosis (Figures 20-22). Therefore, the NAMPT-derived signature is capable of 
accurately predicting poor patient outcomes independently of tumor grade.  
 
 Finally, we analyzed the correlation of our NAMPT-derived signature with other 
proposed mutations that have been proposed to be drivers of the malignant status of 
glioblastoma tumors [175, 191].  
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Figure 21. GSE4290 grade stratification according to NAMPT-driven signature correlation. 
Individual stratification of the gene dataset according to NAMPT expression and its correlation with the other 
elements of the gene signature. (A) Gliomas (Grade I-IV) (B) Oligodendroglioma (Grade II) (C) Astrocytoma 
(Grade III) (D) Glioblastoma (Grade IV) 
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Figure 22. GSE4212 grade stratification according to NAMPT-driven signature correlation. 
Individual stratification of the gene dataset according to NAMPT expression and its correlation with the other 
elements of the gene signature. (A) Gliomas (Grade I-IV) (B) Oligodendroglioma (Grade II) (C) Astrocytoma 
(Grade III) (D) Glioblastoma (Grade IV)  
 
We found that our signature predicts an enrichment of IDH1 mutations in patients 
negative for our signature, indicating a better prognosis in patients with IDH1 mutations 
(Figures 23-24). 
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Figure 23. Heat map showing IDH1 mutation status of patients. IDH1 mutation status according to NAMPT levels 
and expression of the whole signature (GSE16011) 
 
On the other hand, most, if not all, gliomas with EGFR amplifications showed strong 
positive correlation with our NAMPT-derived signature (Figures 24-25). 
 
Figure 24. Percentage of total tumors with mutations in IDH1 or EGFR mutations or amplifications according to 
NAMPT levels Tumors showing low NAMPT expression (NAMPT -, ☐, white bars) and high NAMPT expression 
(NAMPT +, , black bars) are accounted from the heatmaps of figure 23 and figure 25. The bars graph show 
percentage of tumors harboring IDH1 mutation (left) and EGFR amplification (right). NAMPT – indicates low 
NAMPT expression. NAMPT + indicates high NAMPT expression 
 
Figure 25. Heatmap showing EGFR amplification status of patients. EGFR amplification status according to 
NAMPT levels and expression of the whole signature (GSE16011) 
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Therefore, we confirmed that NAMPT is a potent oncogene that confers CIC-like 
properties, which are responsible for the poorer responses and patient prognoses 
associated with glioblastoma.  
 
Table 7. Effect of TMZ and FK866 treatment. Either Mass cultures or tumorspheres treatment over NAMPT-
expressing cells. 
 Monolayer - Monotherapy 
 SF268 U251MG 
 FK866 (nM  SD) TMZ (μM  SD) FK866 (nM  SD) TMZ (μM  SD) 
sh 8.3  0.8 163.2  2.2 22.3  0.6 203.5  4.8 
v 5.2  0.9 165.4  1.9 20.7  0.7 194.1  3.4 
NAMPT 2.8  0.3 173.6  2.1 15.3  1.2 201.4  5.3 
 
 Tumorspehres - Monotherapy 
 SF268 U251MG 
 FK866 (nM  SD) TMZ (μM  SD) FK866 (nM  SD) TMZ (μM  SD) 
sh 9.5  0.9 174.1  3.6 27.3  1.4 221.4  3.2 
v 6.1  1.2 169.8  2.1 18.6  1.9 224.5  1.7 
NAMPT 2.5  0.4 173.3  3.2 11.3  1.3 221.6  4.7 
 
 Monolayer - Combined 
 SF268 U251MG 
 FK866 + 100 μM TMZ (nM  SD) FK866 + 150 μM TMZ (nM  SD) 
sh 6.1  0.2 19.4  0.7 
v 2.4  0.4 14.3  1.3 
NAMPT 0.2  0.4 5.1  1.4 
 
 Tumorspheres - Combined 
 SF268 U251MG 
 FK866 + 100 μM TMZ (nM  SD) FK866 + 150 μM TMZ (nM  SD) 
sh 7.3  0.7 25.4  1.8 
v 4.2  0.3 17.1  0.9 
NAMPT 0.5  1.1 7.2  0.7 
 
7.1.6. NAMPT is a suitable target on glioma CICs 
 
NAMPT is essential for biosynthesis of NAD. Inhibition of NAMPT may lead to depletion of 
NAD+, which in turn inhibits ATP synthesis. This effect eventually causes attenuation of 
cancer cell proliferation and death. Therefore, NAMPT was proposed as an interesting 
therapeutic target. Our data support this idea, particularly with respect to brain tumor 
patients with a NAMPT signature, as these patients have poor prognoses.  
FK866, a NAMPT inhibitor [153, 192], was tested as a possible therapy for gliomas in mass 
cultures and tumorspheres representing CIC populations. NAMPT-overexpressing cells 
were more sensitive to FK866 in mass cultures than parental cells and NAMPT- 
underexpressing cells. As standard treatment, Temozolomide (TMZ) toxicity was also 
assessed both individually and in combination with FK866 (Table 6).  We assessed FK866-
 
 
59 
induced toxicity in tumorspheres and observed that FK866 was effective against this 
CIC population (Table 6). Interestingly, the combined treatment with TMZ slightly 
sensitized these values, both in mass cultures and tumorspheres suggesting this 
combination as an effective therapy (Table 6, Figure 26).  Thus, we believe that NAMPT 
inhibitors, in combination with TMZ may represent a new therapy for glioma CIC 
populations, particularly in patients expressing high levels of the gene signature.  
 
Figure 26. Sphere-formation assay using FK866 inhibitor. (A) Number of spheres after four days of the 
treatment. Treated spheres with NAMPT inhibitor (v + Fk866, sh + FK866, NAMPT + FK866, , green bars) are 
compared to its non-treated homologous (NAMPT, , black bars; v, , grey bars, sh, ☐, white bars). 
Treatment indicated was at single dose only (IC50) (B) Sphere size was also indicated (*, p< 0.05 to NAMPT).  
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7.2. COLORECTAL CANCER 
 
7.2.1. NAMPT correlates with colon cancer clinical outcomes regardless of tumor 
staging 
 
To confirm the clinical relevance of NAMPT expression in colon cancer, we analyzed 
publicly available human colon cancer tumor datasets for NAMPT levels (Figure 27A-
27J).  
 
Figure 27. NAMPT expression analysis in human tumor colon datasets (A) Expression analysis of the human 
tumor dataset GSE20916 shows normalized mRNA levels of NAMPT in normal-non tumoral tissue (N), non-sorted 
out colon tumor tissue (T-C), colon carcinoma (T-CR) and colon adenocarcinoma (T-A). (B) Expression analysis 
of the human tumor dataset GSE10950 shows normalized mRNA levels of NAMPT in human tumor samples (T) 
compared to the normal-non tumoral tissue (N). (C) Patients in GSE20916 transcriptional database shown in 
(A) were classified individually by a crescent NAMPT gene expression level. (D) Patients in GSE10950 shown in 
(B) were classified individually by a crescent NAMPT gene expression level (E) Patients included in GSE18105 
were classified individually by a crescent NAMPT gene expression level (F) Patients included in GSE8671 
dataset were classified individually by a crescent NAMPT gene expression level (G) Expression analysis of the 
human tumor dataset GSE18105 shown in (E) shows that NAMPT is statistically overexpressed in tumors 
compared to normal tissue. (H) Expression analysis of NAMPT in the human tumor dataset GSE8671 shown in (F) 
(I) Expression analysis of NAMPT in the human tumor dataset GSE4183 (J) Patients in GSE4183 shown in (I) were 
classified individually by a crescent NAMPT gene expression level. (K) Overall survival analysis of colon tumor 
dataset GSE17538 for NAMPT expression [n=39 NAMPT low; n=193 NAMPT high; p=0.027 with log-rank analysis]. 
 
After extensive research on the different datasets, including GSE20916 (Figure 27A, 27C), 
GSE10950 (Figure 27B, 27D), GSE18105 (Figure 27G, 27E), GSE8671 (Figure 27H, 27F) and 
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GSE4183 (Figure 27I, 27J), we determined that colon tumors express more NAMPT than 
healthy bowel tissue.  
To further evaluate the potential correlation between NAMPT expression and patient 
outcome, we generated Kaplan-Meier survival curves from the GSE17538 dataset, for 
which clinical data is available, by sorting out patients based on NAMPT levels (high 
and low expression groups). High levels of NAMPT correlated with poor prognosis (Figure 
27K). 
 
7.2.2. NAMPT strengthens tumorigenic properties by enriching the cancer initiating cell 
phenotype  
 
Figure 28. Functional analysis and CIC-like properties in cells according to NAMPT expression. (A, B) qRT-PCR 
shows NAMPT overexpression in either HCT116 (A) or LS180 (B). (C, D) Western blot analysis shows NAMPT 
overexpression and NAMPT silencing with shRNA in HCT116 (C) and LS180 (D). We now compare cell 
properties of cells expressing only a shRNA against NAMPT (sh, ☐, white bars) or NAMPT endogenous 
overexpression (NAMPT, , black bars) to parental expressing only vector (v, , grey bars) (E, F) Analysis of the 
growth curve (G, H) Soft-agar assay showing number of colonies per field (I, J) Cell line-derived xenografts in 
either HCT116 (I) or LS180 (J). (K, L) Analysis of clone phenotypes [holoclones – black, meroclones – grey, 
paraclones – white] (M) The tumorsphere phenotype from cell lines expressing different levels of NAMPT. (N) 
sphere number (O) sphere size (P) CD133 analysis with FACS (Q) CIC-derived xenografts are shown from cell 
lines expressing different levels of NAMPT. A total of 103 cells growing as tumorspheres derived from HCT116 
and LS180 (expressing only vector or overexpressing the NAMPT gene) were subcutaneously injected into 
mice. Four injections per cell line were performed. After 30 days, tumors were measured and extracted. (R) 
Tumor-formation efficacy accounted as a percentage over HCT116 and LS180 derived xenografts (, red 
bars, percentage of tumors formed; , Black bars, size of the tumors.) [*, p< 0.05; **, p< 0.01; ***, p< 0.001 
compared to vector] 
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To explore the causal role of NAMPT, we studied whether NAMPT promotes 
tumorigenicity in colon cancer cells.  
 
We ectopically overexpressed NAMPT cDNA in the human colon cancer cell lines 
HCT116 (p53 null) (Duke’s type D) and LS180 (Duke’s type B), and selected transfectants 
to create a stable pool (NAMPT) (Figure 28A-2D). As proof of concept, we also 
counteracted the endogenous NAMPT gene expression by expressing a small hairpin 
RNA against NAMPT (sh), producing a daughter cell line expressing reduced levels of 
the enzyme (Figure 28A-28D). Data from a second shRNA can be observed in the Figure 
S1. We then compared the behavior of the parental cell line (expressing only vector, V) 
with that of NAMPT-overexpressed (NAMPT) or NAMPT-silenced (sh) isogenic daughter 
cells. The NAMPT-overexpressed cells grew faster than the parental cells, indicating that 
NAMPT confers a proliferative advantage (Figure 28E-28F), while the NAMPT-silenced 
cells grew slower than the parental cells, thus confirming the role of NAMPT in tumor 
proliferation. We also determined the ability of the clones to grow in anchorage-
independent conditions. We seeded 104 cells from parental or NAMPT-overexpressing 
clones in soft-agar and cultured the cells for 3 weeks. While the parental HCT116 and 
LS180 cell lines produced only a few medium-sized colonies, NAMPT-overexpressing 
clones produced an increased number of larger colonies (Figure 28G-28H). On the 
other hand, the number of colonies produced by NAMPT-silencing cells was reduced 
compared with the parental cells (Figure 28G-28H).  
 
We found similar results using a second shRNA against NAMPT (sh-B) to avoid 
overlapping effects (Figure 29C). In a similar assay, we determined the ability of clones 
to overcome apoptosis in the absence of cell-to-cell contact. We measured the 
capability to form colonies when cells were seeded at a very low density. After 2 weeks 
post-seeding, NAMPT-expressing clones were able to increase the number and size of 
the colonies, while clones expressing low NAMPT were able to form only a few small-
sized colonies (Figure 30A, 30B).  
 
To confirm these properties in a physiological setting, we injected either parental 
HCT116 or LS180 and NAMPT-overexpressed or NAMPT-silenced clones into nude mice 
and followed the xenograft growth over time. NAMPT-expressing tumors grew more 
rapidly and to a larger size (and thus shorter mice endpoint) than parental cell lines 
over the same period of time (Figure 28I-28J), thus confirming the potential 
oncogenicity of NAMPT in vivo.  
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To examine whether NAMPT modifies the migration capability related to invasiveness 
and metastasis, we performed an in vitro migration assay in a Boyden chamber. After 
24 and 48 hours post-seeding, more NAMPT-overexpressing cells migrated to the 
bottom of each well of the chamber (Figure 30C, 30D), indicating the role of NAMPT on 
tumor migration. 
 
Figure 29. Effect of a second shRNA against NAMPT in the tumorigenic capability of tumor cells. 
(A) Western blot analysis shows NAMPT protein depletion using a second sh (sh-B) in HCT116 (B) and LS180. (C) 
Clonogenic assay using a second sh-B against NAMPT (sh-B, , dark blue bars) (D) Tumorspheres assay using a 
second sh-B against NAMPT (E) Analysis of clone phenotypes [holoclones – black, meroclones – grey, 
paraclones – white] (F) CD133 analysis using a sh-B against NAMPT [*, p<0.05; **, p<0.01 compared to the 
vector expressing only cells]. 
 
NAMPT overexpression correlated with poor patient prognoses (Figure 27K). It has been 
proposed that CICs are primarily responsible for tumor relapse and poor therapeutic 
responses, as CICs are able to reconstitute entire tumors. To analyze the cancer-
initiating cell properties induced by NAMPT, we cultured cells at low densities to form 
independent colonies comprising individual clones, which were previously classified as 
holoclones, meroclones and paraclones based on their ability to reconstitute tumors 
from a single cell [171-174]. Holoclones are believed to be derived from stem cells, 
while paraclones are differentiated cells that are incapable of reconstituting a culture 
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(Figure 28K-28L). Meroclones are intermediate phenotypes between holo- and 
paraclones (Figure 30E). The percentage of holoclones in NAMPT-expressing cells was 
increased from 45% to 70% in HCT116 (Figure 28K) and from 50% to 65% in LS180 (Figure 
28L), while the percentage of holoclones was reduced in cells expressing NAMPT shRNA 
(Figure 28K-28L), indicating a relationship between NAMPT and the CIC phenotype.  
 
Figure 30. Tumorigenic properties induced by NAMPT 
We compare cell properties of cells expressing only a shRNA against NAMPT (sh, ☐, white bars) or NAMPT 
endogenous overexpression (NAMPT, , black bars) to parental expressing only vector (v, , grey bars)  (A) 
Clonogenicity assay in HCT116 and (B) LS180. (C, D) Migration assay measured in Optical Density (595 nm) 
using a Boyden chamber in (C) HCT116 and (D) LS180. (E) Representative picture of clone phenotypes. [*, p< 
0.05; **, p< 0.01; ***, p< 0.001 compared to vector] 
 
We found similar results using the second NAMPT shRNA (Figure 29) 
 
Next, we tested the ability of cells with different levels of NAMPT expression to form 
tumorspheres, another surrogate assay for the cancer stem-like phenotype [174, 184-
186]. The cells were seeded and visualized 21 days later (Figure 28M). The parental cells 
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formed spheres at this stage, which were considered 1st generation tumorspheres. The 
number and size of tumorspheres derived from the cells with increased NAMPT 
expression was significantly higher than those derived from the control and parental 
cells (Figure 28N, 28O). Similar results were found using the second NAMPT shRNA (Figure 
29D). 
 
Figure 31. CD133+ single cell derived tumorspheres of HCT116. (A) HCT116 CD133+ cells subpopulation with 
different NAMPT expression levels being sorted through flow cytometry (B) Number of tumorspheres from 150 
CD133+ positive cells selected individually. The size of tumorspheres is showed in the picture above the 
graphic. 
 
To finally confirm these data, we tested the ability of cells with different levels of NAMPT 
expression to form tumorspheres from one isolated single cell, another surrogate assay 
for the CIC-like phenotype [174, 184-186]. The cells were seeded at one cell per well 
and visualized 21 days later (Figure 31). The parental cells formed spheres at this stage, 
which were considered 1st generation tumorspheres. The number and size of 
tumorspheres derived from the cells with increased NAMPT expression was significantly 
higher than that derived from the control and parental cells (Figure 31). 
 
In addition, FACS analysis of tumor cells showed higher stem cell phenotypic marker 
expression, which correlated with NAMPT expression. NAMPT-overexpressed cells 
showed increases in CD133+ in both parental cell lines (Figure 28P), while NAMPT-
silenced cells showed clear reductions in the CD133+ percentage of cells (Figure 28O). 
The second shRNA, sh-B, showed similar results (Figure 27).  
 
To examine the tumor suppressor role of p53 we generated NAMPT-overexpressed and 
NAMPT-silenced daughter cell lines that were p53 isogenic derivatives of HCT116 p53+/+ 
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(Figure 32A-32B). We found similar results in this cell line (Figure 32C-32H), indicating that 
these NAMPT-induced tumorigenic properties are p53-independent.  
 
Figure 32. Tumorigenic NAMPT-dependent capabilities in HCT 116 +/+ p53 wild type. 
(A) qRT-PCR shows NAMPT overexpression in either HCT116 (B) Western blot analysis shows NAMPT 
overexpression and NAMPT silencing with shRNA in HCT116. We compare cell properties of cells expressing 
only a shRNA against NAMPT (sh, ☐, white bars) or NAMPT endogenous overexpression (NAMPT, , black 
bars) to parental expressing only vector (v, , grey bars) (C) Analysis of the growth curve (D) Clonogenicity (E) 
Analysis of clone phenotypes [holoclones – black, meroclones – grey, paraclones – white] (F) CD133 analysis 
with FACS (G) Cell line-derived xenografts (H) Tumorsphere assay (I) qRT-PCR analysis for effectors controlling 
CSC-like properties (J) qRT-PCR analysis for effectors controlling EMT [*, p< 0.05; **, p< 0.01; ***, p< 0.001 
compared to vector] 
 
 
To confirm that these potential tumor-initiating cells were responsible for tumor initiation 
in a physiological setting, we injected 103 tumorsphere-derived cells from either 
parental or NAMPT-overexpressing clones. Clones overexpressing NAMPT were able to 
form higher number of visible and larger tumors after a month in both cell lines (Figure 
28Q-28R), thus confirming the role of NAMPT in tumor initiation in vivo. 
 
7.2.3. NAMPT induces pluripotency via signaling pathways that control reprogramming 
 
To support this finding, we decided to explore the correlation between NAMPT 
expression and cell reprogramming. To this end, we analyzed whether the iPSC 
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transcriptional core formed by SOX2, OCT4 and NANOG was altered by NAMPT levels. 
By qRT-PCR, we individually analyzed each transcript and found that NAMPT-
overexpressing cells significantly induced SOX2, OCT4 and NANOG mRNA expression, 
while cells expressing shRNA showed reduced levels (Figure 33A). The HCT116 p53+/+ 
isogenic derivative behaved similarly (Figure 32I).  
 
Figure 33. EMT and stem pathway effectors analysis according to NAMPT expression.  
We compare expression levels of cells expressing only a shRNA against NAMPT (sh, ☐, white bars) or NAMPT 
endogenous overexpression (NAMPT, , black bars) to parental expressing only vector (v, , grey bars) (A) 
qRT-PCR analysis of Stem genes in HCT116 and LS180 according to NAMPT expression: SOX2, OCT4 and 
NANOG. [*, p<0.05; **, p<0.01; ***, p<0.001 with t-test]. (B) qRT-PCR analysis of EMT genes in both cell lines 
according to NAMPT expression: TWIST1, VIM and SNAI1 [*, p<0.05; **, p<0.01 with t-test]. (C) Correlation 
between number of tumorspheres and NAMPT mRNA levels. We harvested four fresh tumor colon samples 
from patients. After tissue disaggregation, we directly measured NAMPT levels by qRT-PCR and, in parallel, 
seeded 3000 cells to measure the number of formed tumorspheres. Then, we plotted to establish a 1 to 1 
correlation (Pearson) between the level of NAMPT and the number of tumorspheres. (D) As in (C), a 1 to 1 
correlation between NAMPT and CD133 expression levels is shown. (E) Analysis of GSE20916 human tumor 
colon transcriptional dataset for tumor samples compared to normal-non tumoral tissue for CD133, SOX2, 
CD44 and SOX9.  
 
The epithelial-mesenchymal transition (EMT) is an essential step that mediates tumor 
reprogramming and metastasis. Several genes are expressed during EMT induction [189, 
190]. We tested whether NAMPT overexpression upregulates some of these genes. We 
found that the expression of TWIST1, VIM and SNAI1 was induced in NAMPT-
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overexpressing cells (Figure 33B). The HCT116 p53+/+ isogenic derivative behaved 
similarly (Figure 32J). 
 
Next, we harvested 4 fresh human colon cancer samples from patient direct derived 
tumors, PDXs, grown in mice [193].   
After tissue disaggregation, tumor samples were dissociated into single-cell suspension 
by enzymatic digestion. Afterwards, the cell lines derived and established from PDX 
were maintained during several passages to remove fibroblasts. We then measured 
NAMPT levels by qRT-PCR and seeded 3000 cells in parallel to assess the number of 
formed tumorspheres. Then, we plotted to establish 1 to 1 correlation between the level 
of NAMPT and the number of tumorspheres. We found a strong direct correlation of the 
tumorsphere number and NAMPT levels of each tumor (Figure 33C). We also found a 
 
Figure 34. Analysis of NAMPT expression levels according to factors controlling CSC-like properties in human 
colon tumors and a additional cell line. 
(A) GSE34053 database, from human colon tumors, have transcription profiles of sorted CD133+ cells. We 
analyzed the correlation of CD133+ cells with NAMPT expression along with the following: HES1, OCT4 and 
SOX9. (B) GSE14774 database includes transcription profiles of a supplementary colon cancer cell line, HT-29, 
both in monolayer culture and tumorspheres. We analyzed the correlation of NAMPT on either monolayer or 
tumorspheres along with the following: HES1, OCT4 and SOX9. 
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correlation  between NAMPT and CD133 mRNA levels, thus identifying for the first time a 
direct correlation of NAMPT with this cancer stem cell-like marker (Figure 33D). 
 
Figure 35. Effect of the addition of the NAMPT product NMN 
We added 1 mM NMN to cells expressing the shRNA against NAMPT (sh+N, , blue bars) and compared 
different properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or 
NAMPT endogenous overexpression (NAMPT, , black bars).  (A, B) growth curve, (C, D) clonogenic assay, (E) 
CD133 percentage of cells, (F) number of tumorspheres, (G) stem cell pathway effectors and (H) EMT 
effectors [*, p<0.05; **, p<0.01; ***, p<0.001 compared to sh].  
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To set a physiological background for NAMPT-driven CIC markers on CD133+ cells, we 
used the GSE34053 database from human colon tumors, which included transcription 
profiles of sorted CD133+ cells.  
 
First, we observed that CD133+ cells expressed higher levels of NAMPT (r=0.317) along 
with higher levels of SOX2 (r=0.394), CD44 (r=0.899) and SOX9 (r=0.597) (Figure 33E). To 
strengthen these data, we explored GSE34053 from human colon samples taken from 
stage II biopsies (Figure 34A). We also found that CD133+ sorted cells expressed higher 
levels of NAMPT, newly identifying OCT4 and SOX9 as CIC markers. Finally, we 
supplemented our data with analysis of GSE14773, which had transcription profiles for 
both monolayer and tumorsphere cultures of the HT-29 cell line (Duke’s B). We found 
that NAMPT is overexpressed in tumorspheres and associates with the CIC markers 
(Figure 34B). 
 
7.2.4. Recovery of the NAMPT-Induced phenotype by NMN and extracellular NAMPT 
(Visfatin, eNAMPT) 
 
NAMPT catalyzes the conversion of nicotinamide to nicotinamide mononucleotide 
(NMN), which is the rate-limiting step in the NAD salvage pathway. If the enzymatic 
activity of NAMPT is directly responsible for these observed phenotypes, the phenotype 
should be recovered by directly adding the product of the enzyme to cells. Therefore, 
we repeated the previous surrogate experiments and added saturating concentrations 
of NMN to cells expressing low levels of NAMPT (sh supplemented with NMN, sh+NMN). 
In these experiments, we rescued the parental phenotypes by supplying the cells with 
the NAMPT metabolic product NMN (Figure 35A-35F). In all cases, the growth rate 
(Figure 35A, 35B), the number of colonies (Figure 35C, 35D), CD133+ fraction of cells 
(Figure 35E) and number of tumorspheres (Figure 35F) were recovered in the cells with 
downregulated NAMPT expression with abundant NMN in the medium, behaving 
similarly to the parental cells. However, they did not exhibit the same increased levels of 
tumorigenicity induced by NAMPT overexpression (Figure 35A-35F). The holoclone 
number was also rescued by NMN addition (Figure 36A). Similar results were found in the 
p53 wild type isogenic derivative cell line (Figure 37A-37E). 
 
We also found similar restoration of transcription results when metabolic NMN product 
was added exogenously, NMN rescued the transcription of Stem and EMT genes to the 
parental cell levels in cells expressing the shRNA against NAMPT (sh) (Figure 35G, 4H). 
The same effect was observed for HCT116 p53+/+ (Figure 35F, 35G). 
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Figure 36. Effect on the clonal heterogeneity after addition of the NAMPT product NMN, or the extracellular 
NAMPT (visfatin) to cells depleted of NAMPT. 
(A) Clonal heterogeneity analysis adding 1 mM NMN in both cell lines [holoclones – black, meroclones – grey, 
paraclones – white]  (B) Clonal heterogeneity analysis adding 60 ng/mL visfatin. 
 
Extracellular NMN also recover the size al number of tumorspheres when CD133+ cells 
were seeded individually (Figure 31), however, size and number only reach those of 
parental cells and not the increased induced by NAMPT overexpression (Figure 31) 
NAMPT is also known to act as an extracellular soluble protein named visfatin, of which 
its activity is not clearly related to the enzymatic activity of the protein [187, 188]. 
Therefore, we explored the phenotypic effects of extracellular visfatin supplementation 
in NAMPT-silenced cells and found that these cells were rescued, similar to the adding 
of NMN (Figure 38A-38H). However, as before, the cells did not exhibit the total 
increased levels of tumorigenicity induced by NAMPT overexpression (Figure 38A-38H). 
The holoclone number was also rescued by visfatin addition (Figure 36B). Similar results 
were found in the p53 isogenic derivative cell line (Figure 39A-39G). 
 
We also found similar restoration of transcription results when extracellular visfatin was 
added exogenously. Exogenous NAMPT rescued the transcription of Stem and EMT 
genes to the parental cell levels in cells expressing the shRNA against NAMPT (sh) 
(Figure 38G-38H). The same effect was observed for HCT116 p53+/+ (Figure 39F-39G). 
 
These results clearly indicate that NAMPT gene overexpression provides the protein with 
properties beyond those associated with its enzymatic function in the salvage pathway, 
conferring CIC-like properties to the cells in which is expressed. 
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Figure 37. Effect of the addition of the NAMPT product NMN cells depleted of NAMPT in HCT 116 +/+ p53 wild 
type. 
We added 1 mM NMN to cells expressing the shRNA against NAMPT (sh+N, , blue bars) and compared 
different properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or 
NAMPT endogenous overexpression (NAMPT, , black bars).  (A) growth curve, (B) clonogenic assay, (C) 
CD133 percentage of cells, (D) number of tumorspheres, (E) number of holoclones (F) stem cell pathway 
effectors and (G) EMT effectors [*, p<0.05; **, p<0.01; ***, p<0.001 compared to sh].  
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Figure 38. Effect of the addition of extracellular NAMPT (visfatin) to cells depleted of NAMPT 
We added 60 ng/mL visfatin to cells expressing the shRNA against NAMPT (sh+N, , red bars) and compared 
different properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or 
NAMPT endogenous overexpression (NAMPT, , black bars).  (A, B) growth curve, (C, D) clonogenic assay, (E) 
CD133 fraction, (F) number of tumorspheres, (G) stem cell pathway effectors and (H) EMT effectors [*, p<0.05; 
**, p<0.01; ***, p<0.001 compared to sh]. 
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Figure 39. Effect of the addition of extracellular NAMPT (visfatin) to cells depleted of NAMPT in HCT 116 +/+ p53 
wild type. We added 60 ng/mL visfatin to cells expressing the shRNA against NAMPT (sh+N, , red bars) and 
compared different properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white 
bars) or NAMPT endogenous overexpression (NAMPT, , black bars).  (A) growth curve, (B) clonogenic assay, 
(C) CD133 fraction, (E) number of tumorspheres, (E) number of holoclones (F) stem cell pathway effectors 
and (G) EMT effectors [*, p<0.05; **, p<0.01; ***, p<0.001 compared to sh] 
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7.2.5. SIRT1 Modulates NAMPT-Driven Tumorigenic Properties in Colon Cancer. 
 
Since NAD+ is a rate-limiting cofactor for the Sirtuins, its modulation is emerging as a 
valuable tool to regulate Sirtuin function [194].  
 
Figure 40. NAMPT expression analysis in correlation with each SIRTUINs family members in GSE20916 
(A) Analysis of the correlation of NAMPT with the Sirtuin family. We performed this analysis using GSE20916. 
 
SIRT1 tends to either activate or repress transcription of specific target genes by H3 
deacetylation at lysine residues [151]. SIRT1 has been suggested to be involved in 
cancer in a context-dependent manner [195]. As SIRT1 has a direct NAD-dependent 
mechanism of action, we wanted to explore the causal role of this in NAMPT-related 
colon cancer. 
 
First, we explored GSE20916 for SIRT family genes correlation to NAMPT  in tumor samples, 
and we found that only SIRT1 expression had a significant correlation with NAMPT 
expression in tumors (Figure 40).  
 
To explore the causal effect of Sirtuin depletion on NAMPT-driven tumorigenic 
properties, we decided to use sirtinol, a specific SIRT1 and SIRT2 inhibitor, on NAMPT-
expressing clones to examine the effect on these properties. By using sirtinol, we 
significantly decreased the growth rate in both cell lines (Figure 41A-42B) as observed 
by the effect on the number of colonies in clonogenicity (Figure 41C-41D), the CD133+ 
fraction (Figure 41E), the number of tumorspheres (Figure 41F) and the transcriptional 
panel for stem cell markers genes and EMT effectors (Figures 41G-41H).  
 
Similar recovery was found in the number of holoclones (Figure 42A). We found similar 
results for both inhibitors in the p53 isogenic derivative HCT116 p53+/+ (Figure 43). 
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Figure 41. Effect of the addition of the Sirt1 inhibitor Sirtinol, or the NAMPT inhibitor (FK866) to cells 
overexpressing NAMPT. 
We added 1 µM sirtinol to cells overexpressing NAMPT (NAMPT+S, , orange bars) and compared different 
properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or NAMPT 
overexpression only (NAMPT, , black bars).  (A, B) growth curve, (C, D) clonogenic assay, (E) CD133 
percentage of cells, (F) number of tumorspheres, (G) stem cell pathway effectors and (H) EMT effectors [*, 
p<0.05; **, p<0.01; ***, p<0.001 compared to NAMPT overexpression only].  
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Figure 42 Effect on the clonal heterogeneity after addition of the SIRT1 inhibitor (Sirtinol), or NAMPT inhibitor 
(FK866) to cells overexpressing NAMPT. 
(A) Clonal heterogeneity analysis adding 1 μM Sirtinol in both cell lines [holoclones – black, meroclones – grey, 
paraclones – white]  (B) Clonal heterogeneity analysis adding 2.5 nM of FK866. 
  
To confirm that NAMPT is the key factor that directly regulates these properties, as a 
counterpart of the above experiments, we pharmacologically inhibited NAMPT using a 
potent inhibitor, FK866, and found an equivalent reduction of tumorigenic properties 
(Figures 44-44P, 42 and 45). 
  
These data confirm that NAMPT-induced tumorigenic properties and activation of both 
stem cells and EMT transcriptional cores are modulated by SIRT1 which functions as a 
mediator of the oncogene-like NAMPT effect in the human colon cancer context. 
 
7.2.6. NAMPT regulation of cancer stem cell pathways correlated with SIRT1 and PARP1. 
 
NAD+ is also known to be a co-substrate of ADP‐ribosyltransferases (e.g., PARPs). PARP 
proteins have also been suggested to have a significant impact on cancer progression 
[196]. With the aim of identifying the pathways that induce the cancer stem cell-like 
properties, we correlated NAMPT expression with stem cell pathways in several in silico 
colon cancer retrospective studies. To that end, we applied a filter of those elements 
involving a triple crossover between NAMPT, SIRT1 and PARP1. Thus, we explored the 
GSE20916 transcriptional database through meta-analysis (using bioinformatics tools 
provided by the R2 platform). We found a significant correlation among NAMPT, SIRT1 
and PARP1 in colon tumor samples (Figure 46A). When we compilated all transcription 
genes that correlated with all these three genes, NAMPT, SIRT1 and PARP1, and 
analyzed the KEGG pathways represented we found strong correlations with the Notch 
signaling pathway (p<0.01), Hippo signaling pathway (p<0.01) and Wnt signaling 
pathway (p<0.01) (Figure 46B).  
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Figure 43. Effect of the addition of the Sirt1 inhibitor Sirtinol to HCT 116 +/+ p53 
Left half of the figure: we added 1 µM sirtinol to cells overexpressing NAMPT (NAMPT+S, , orange bars) and 
compared different properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white 
bars) or NAMPT overexpression only (NAMPT, , black bars).  (A, B) growth curve, (C, D) clonogenic assay, (E) 
CD133 percentage of cells, (F) number of tumorspheres, (G) stem cell pathway effectors and (H) EMT 
effectors [*, p<0.05; **, p<0.01; ***, p<0.001 compared to NAMPT overexpression only].  
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Figure 44. Effect of the addition of the NAMPT inhibitor (FK866) to cells overexpressing NAMPT We added 2.5 
nM FK866 to cells overexpressing NAMPT (NAMPT+F, , green bars) and compared different properties to 
parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or NAMPT overexpression only 
(NAMPT, ■, black bars).  (A, B) growth curve, (C, D) clonogenic assay, (E) CD133 fraction, (F) number of 
tumorspheres, (G) stem cell pathway effectors and (H) EMT pathway effectors [*, p<0.05; **, p<0.01; ***, 
p<0.001 compared to NAMPT overexpression only].  
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Figure 45. Effect of the addition of the NAMPT inhibitor (FK866) to HCT 116 +/+ p53 cells overexpressing NAMPT. 
We added 2.5 nM FK866 to cells overexpressing NAMPT (NAMPT+F, , green bars) and compared different 
properties to parental expressing only vector (v, , grey bars), shRNA only (sh, ☐, white bars) or NAMPT 
overexpression only (NAMPT, , black bars).  (I, J) growth curve, (K, L) clonogenic assay, (M) CD133 fraction, 
(N) number of tumorspheres, (O) stem cell pathway effectors and (P) EMT pathway effectors [*, p<0.05; **, 
p<0.01; ***, p<0.001 compared to NAMPT overexpression only]. 
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We found 21 significant and common elements in the triple crossover for the Hippo 
pathway (Figure 46C), 6 for Notch (Figure 46D) and 17 for Wnt signaling pathway 
(Figure 46E).  
 
Figure 46. NAMPT-derived Gene Signature correlation with Stem Pathway Effectors 
(A) Heatmap from human colon tumor dataset GSE20916 showing tumor correlation levels of NAMPT, SIRT1 
and PARP1. (B) KEGG analysis of NAMPT, SIRT1 and PARP1 showing the correlation with four major pathways 
controlling CSC-like properties. (C) KEGG analysis of Hippo pathway correlating NAMPT, SIRT1 and PARP1 with 
statistically common effectors of the pathway. (D) KEGG analysis of Notch pathway correlating NAMPT, SIRT1 
and PARP1 with statistically common effectors of the pathway. (E) KEGG analysis of Wnt pathway correlating 
NAMPT, SIRT1 and PARP1 with statistically common effectors of the pathway. 
 
 
82 
 
These pathway correlations reinforce the hypothesis that NAMPT modulates SIRT1 and 
PARP1 to control the cellular functions that promote proliferation and pathways, thus 
regulating EMT and tumor dedifferentiation. 
 
7.2.7. NAMPT triggers a gene signature which correlates with poor survival in human 
colon cancer 
 
NAMPT induces genes associated with effectors controlling CSC pathways, which 
increase tumorigenicity and expression of the CIC-like phenotype.  
Table 8. Correlation analysis using GSE20916 of the prognosis predictive gene set driven by NAMPT. We show 
correlations of each element with NAMPT. All data shown is highly significant (p< 0.01). 
 
 
 
 
 
 
 
 
 
 
It is possible that these factors can be used to predict the prognoses of human colon 
cancer patients regardless of tumor staging. We chose NAMPT and genes activated by 
its overexpression showing high correlation (Pearson, R) in human tumors (Table 7), 
including YAP1, MYC, DVL2, MMP7, CSNK2A1 and ADAM17 (Figure 47A). All these genes 
define a highly representative gene signature (Figure 47B). All these transcripts were 
increased in colon cancer patient tissue samples compared to their levels in 
corresponding normal bowel tissue (Figure 47A). However, also aproximately a 30% 
tumor samples showed low expression signature (Figure 47A). 
Through the analysis of the NAMPT-derived signature in different datasets, we observed 
that the incidence of the gene signature was present in all tumor stages including stage 
IV, or metastatic, tumors. Furthermore, comparisons of Kaplan-Meier plots between the 
groups with high expression of the signature and the groups with low expression of the 
signature showed that patients with a positive signature had a poor prognosis (Figure 
47C). Therefore, the NAMPT-derived signature is capable of accurately predicting poor 
patient outcomes independent of tumor grade.  
 
 NAMPT 
Pearson R 
SIRT1 0.702 
PARP1 0.625 
ADAM17 0.856 
CSNK2A1 0.824 
MMP7 0.802 
DVL2 0.780 
MYC 0.776 
YAP1 0.915 
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Therefore, we confirmed that NAMPT is a potent oncogene that confers CIC-like 
properties, which are responsible for the poorer survival probability to patients with 
colon cancer.  
 
Figure 47. Analysis of NAMPT-Related Signature Correlates with Poor Prognosis 
(A) NAMPT-derived signature in colon cancer is represented. (B) R2 expression analysis of the gene signature 
triggered by NAMPT in GSE20916 human tumor colon dataset. (C) Overall survival probability comparing the 
patients showing low expression signature vs high expression signature. R2 expression analysis of the gene 
signature triggered by NAMPT in the database in a biased cohort of patients with high signature expression 
[n=10] and low signature expression [n=10] shows poor survival in patients [p=0.013] with log-rank analysis. 
 
7.2.8. NAMPT is a suitable target on colon cancer CICs by either direct inhibition 
monotherapy or in combination with sirtinol or olaparib. 
 
The inhibition of NAMPT may lead to the depletion of NAD+, which in turn inhibits ATP 
synthesis. This effect eventually causes the attenuation of cancer cell proliferation and 
death. Therefore, NAMPT has been proposed as a promising therapeutic target. Our 
data support this idea, particularly with respect to colon tumor patients with an NAMPT 
signature, as these patients have poor prognoses.  
 
FK866, an NAMPT inhibitor [192, 197], was tested as a possible therapy for colon cancer 
tumors in mass cultures and tumorspheres representing CIC populations. NAMPT-
overexpressing cells were more sensitive to FK866 in mass cultures than parental cells 
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and NAMPT-silenced cells (Table 9). Sirtinol and olaparib toxicity was also assessed both 
individually and in combination with FK866 (Table 9). We assessed FK866-induced 
toxicity in tumorspheres and observed that FK866 was effective against this CIC 
population by reducing the IC50 of the drug (Table 9). Interestingly, the combined 
treatment with either sirtinol or olaparib slightly sensitized these values, both in mass 
cultures and tumorspheres, suggesting that these combinations can be used as an 
effective therapy (Table 9). Thus, we believe that NAMPT inhibitors, in combination with 
sirtinol or PARP inhibitors, may represent a new therapy for colon cancer patients, 
particularly in patients expressing high levels of the gene signature. 
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Table 9. NAMPT Is a suitable target in both monolayer tumor cells and tumorspheres 
Cytotoxic analysis of the NAMPT inhibitor FK866 and olaparib or sirtinol shows IC50s of SF268 and U251MG alone or in combination in monolayer culture or Tumorsphere specific assays.  
 
  Monolayer - Monotherapy  
 HCT116  LS180  
 FK866 (nM  SD) Olaparib (nM  SD) Sirtinol (M  SD) FK866 (nM  SD) Olaparib (nM  SD) Sirtinol (M  SD) 
sh 13.71.1   24.72.5 15.31.3 15.31.4  54.23.4 18.42.1 
v 9.40.3   20.81.2  12.61.7 7.81.9  36.84.3 15.91.2 
NAMPT 5.20.8   14.72.7 8.40.9 4.11.3  21.42.2 12.30.8 
 
  Tumorspehres - Monotherapy  
 HCT116  LS180  
 FK866 (nM  SD) Olaparib (nM  SD) Sirtinol (M  SD) FK866 (nM  SD) Olaparib nM  SD) Sirtinol (M  SD) 
sh 19.42.3  37.82.3  10.71.0 26.82.8 68.41.7 13.82.3 
v 17.21.8 28.64.2 4.21.7 20.41.7 43.61.9 8.31.2 
NAMPT 10.51.1  20.32.1  21.1 12.41.8 34.22.5 5.21.5 
 
  Monolayer - Combined  
 HCT116  LS180  
 FK866 + 10 nM Olaparib (nM  
SD) 
FK866 + 1 M Sirtinol (M  SD) FK866 + 10 nM Olaparib (nM  SD) FK866 + 1 M Sirtinol (M  SD) 
sh 9,10.2  7.30.5 10.40.4 9.40.5 
v 3.70.5 5.20.7 5.80.2 8.20.4 
NAMPT 2.10.7 1.10.3 3.31.0 2.30.7 
 
  Tumorspheres – Combined  
 HCT116  LS180  
 FK866 + 10 nM Olaparib (nM  
SD) 
FK866 + 1 M Sirtinol (M  SD) FK866 + 10 nM Olaparib (nM  SD) FK866 + 1 M Sirtinol (M  SD) 
sh 15.70.8 13.21.2 20.61.7 15.71.2 
v 12.70.9 10.30.9 14.52.1 12.60.9 
NAMPT 6.51.4 7.21.1 9.30.8 5.41.5 
For the assay, 5x103 cells were seeded and then treated with the different compound at 11 different concentrations at 1/3 dilutions after 24 hours. Then, 96 hours later, cell viability was 
measured via MTT assay and validated independently by crystal violet staining. IC50 was calculated as the concentration allowing 50% survival compared to day 0 controls. 
Combination experiments were performed testing 11 different concentrations at 1/3 dilutions of FK866 and maintaining same suboptimal concentration of olaparib or sirtinol (as 
indicated) in all tested points. 
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8. DISCUSSION 
8.1. NAMPT overexpression induces cancer stemness and defines a novel tumor 
signature for glioma prognosis. 
 
Gliomas are malignant tumors associated with poor prognosis and low median survival 
time. Among them, glioblastoma is the most common malignant primary brain tumor in 
adults and one of the most lethal human cancers [191, 198, 199]. Glioblastoma is not a 
surgically curable disease because the tumor cells invade the surrounding brain tissue 
and are among the most resistant to radiation and cytotoxic chemotherapy [200, 201]. 
Therefore, new advances in stratification strategies, molecular knowledge and 
treatment approaches are needed. In 2010, Verhaak RG et al set the basis of a 
molecular categorization of Glioblastomas [175], later used by the TCGA. Later studies 
based on tumor sequencing analyses from different tumor areas and paired biopsy at 
diagnosis and recurrent tumor analyses have shown that multiple subtypes can co-exist 
within the same tumor and can change after treatment. We found that NAMPT is 
particularly overexpressed in 3 out of these 4 subtypes. We found that our signature 
predicts an enrichment of IDH1 mutations in patients negative for our signature, 
indicating a better prognosis in patients with IDH1 mutations [202]. On the other hand, 
most, if not all, gliomas with EGFR amplifications showed strong positive correlation with 
our NAMPT-derived signature. 
 
Here, we showed that the NAMPT gene is highly overexpressed in a large percentage 
of glioma tumors, in accordance to Gujar et al recently [155]. This percentage 
increases in late-stage tumors. Furthermore, tumors with high NAMPT expression levels 
were associated with poor prognosis, independently of tumor stage. Ectopic 
overexpression of NAMPT in glioma cells increases its protumorigenic properties, as well 
as its cancer initiating cell-like physiological properties. However, downregulation of 
NAMPT via overexpression of specific shRNAs reduces its tumorigenicity and CIC-like 
properties. We showed that NAMPT activates Stemness maintenance and EMT 
pathways, as demonstrated by the activation of several transcriptional markers. NAMPT 
also activates OSKM factors by activating SOX2, OCT4 and NANOG. Therefore, NAMPT 
overexpression facilitates self-renewal cell properties, resulting in stemness-like 
maintenance, which ultimately leads to increased migration, de-differentiation and 
CIC-dependent resistance to therapy, which are features of glioma tumors.  
 
Nicotinamide phosphoribosyl transferase, NAMPT, catalyzes the conversion of 
nicotinamide to nicotinamide mononucleotide (NMN), which is the rate-limiting step in 
the NAD+ salvage pathway. NAMPT is essential for biosynthesis of NAD+ and has been 
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found to be upregulated in many cancer cells [150, 155, 187, 203]. Inhibition of NAMPT 
can lead to depletion of NAD+, which in turn inhibits ATP synthesis. This effect eventually 
causes attenuation of cancer cell proliferation and death [152, 153, 192, 197, 204]. 
Metabolic switch is a key factor in cellular transformation. Human cancers exhibit 
altered metabolism and depend heavily on glycolysis, the Warburg effect [205]. Due to 
the abnormal consumption of glycolytic end-products and NAD+, tumors have 
dramatically increased glucose needs [150, 155, 203]. This abnormal metabolism is 
enhanced in CICs. Our study showed that NAMPT facilitates increases in CIC subsets, 
defining a novel signature characterized by early development and stem-like property 
maintenance. Our results suggest that CICs in primary gliomas primarily use the NAD+ 
salvage pathway to maintain a full, rich source of nutrients for enzymatic activity, 
leading to tumor progression and eventual reprogramming, which ultimately results in 
relapse. Our data also suggest that CICs have a competitive advantage in any 
nutrient-limiting microenvironment. NMN and visfatin, when supplied to NAMPT-
underexpressing cells, restored the phenotype of the parental cells. NMN may diffuse 
through the membrane supplying the NMN deficient production by NAMPT 
downregulation. Visfatin, as extracellular NAMPT may act biochemically metabolizing 
extracellular nicotinamide into NMN which may diffuse to the cell, restoring the 
parental phenotype. 
 
NAMPT-driven stemness is closely associated with upregulation of the Stem cell 
pathways signaling pathways. Recent studies [44, 45] have highlighted the importance 
of these pathways, which mediated tumor chemoresistance, and its upregulation has 
been linked to radiotherapy resistance in tumor cells derived from glioma CICs. Our 
data are in accordance with most of previous works indicating that stem cell pathways 
upregulation has greater tumorigenic potential in human cancer and that a positive 
correlation exists between glioma stage and NAMPT expression.  
 
Based on the above findings, we explored whether a NAMPT-dependent profile 
comprising NAMPT, CD44, JUN, TEAD4, CSNK1A1, ABCC3, SERPINE1 and HES1 enables 
correct stratification of glioblastoma patients. Our data clearly showed that this NAMPT-
dependent profile correctly separated patients with good prognosis from those with 
bad prognosis. Altogether, our data suggest that NAMPT may be a suitable therapeutic 
target for glioblastoma, especially in patients with poor prognosis. Because NAMPT 
induces the CIC phenotype, we tested whether tumorspheres, as in vitro surrogates for 
tumor CICs, respond to the NAMPT inhibitor FK866. We found that this toxicity driven by 
NAMPT inhibitor could be strengthened in combination with TMZ. We found that glioma 
tumorspheres are sensitive to NAMPT inhibitors, particularly tumorspheres with high levels 
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of NAMPT expression, which indicates that NAMPT inhibition may be a suitable therapy 
for glioblastoma. It has been recently demonstrated that IDH1 mutant gliomas respond 
to NAMPT inhibition [206].  We found that IDH1 wild type correlated to NAMPT 
overexpression (Figure 23). Since, cells overexpressing NAMPT gene, are more sensitive 
to its inhibition, either by NAMPT inhibition alone or in combination with temozolamide 
(Table 7), this data suggest that NAMPT inhibition effect is independent of the IDH1 
mutations and dependent only on the levels of NAMPT expression. Although NAMPT is 
expressed in a wide range of normal tissues, the brain is a very metabolically active 
organ, which may represent a therapeutic window for drug targeting. Furthermore, 
unlike glioma cells, healthy neurons remain in a quiescent, post- mitotic state, 
suggesting that anti-NAMPT combination therapies with conventional drugs that target 
rapidly proliferating cells may have effects on CICs while sparing neurons, supporting 
the use of NAMPT inhibitors in cancer treatment.  
 
8.2. NAMPT is a potent oncogene in colon cancer progression that modulates cancer 
stem cell properties and resistance to therapy through SIRT1 and PARP1. 
 
As mentioned before, NAMPT is a highly conserved protein across mammalian species 
and lower organisms with a key role in metabolism. It has been described that NAMPT is 
highly overexpressed in many tumor types. Our studies in colon cancer are in 
accordance with studies uncovering NAMPT as a potent and targetable oncogene. A 
number of Phase I and II clinical trials involved the use of an NAMPT inhibitor [192, 207], 
and many labs are exploring new drug design targeting NAMPT that offer new 
generation inhibitors.  
 
Chemoresistant tumors rely on NAD-dependent mechanisms to detoxify and provide a 
selective advantage [208, 209]. Here, we show that NAMPT-driven stemness is closely 
associated with the upregulation of stem cell signaling pathways. Recent studies have 
highlighted the importance of these pathways, which mediate tumor chemoresistance, 
and the upregulation of stem cell signaling pathways have been linked to radiotherapy 
resistance in tumor cells derived from colon CICs [210]. Our data are in accordance 
with previous studies indicating that the upregulation of the stem cell pathways has 
greater tumorigenic potential in human cancer and that a positive correlation exists 
with NAMPT expression [211, 212]. 
 
If the enzymatic activity of NAMPT is directly responsible for these phenotypes, the 
phenotype should be recovered by directly adding the product of the enzyme to cells. 
In these experiments, we rescued the parental phenotypes by supplying the cells with 
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the NAMPT metabolic product NMN. In all cases, the cells with downregulated NAMPT 
expression, but with abundant NMN in the medium, behaved similarly to the parental 
cells. However, these cells did not exhibit the increased levels of tumorigenicity induced 
by NAMPT overexpression. Similarly, extracellular supplementation with visfatin in 
NAMPT-silenced cells rescued the parental phenotype, which was similar to adding of 
NMN. However, as before, the cells did not exhibit the total increased levels of 
tumorigenicity induced by NAMPT overexpression. These data may suggest that 
intracellular overexpression of NAMPT may induce independent activities that may 
complement the enhanced tumorigenic properties. However, more research is 
necessary to clarify this point. 
 
As an upstream factor in several pathways controlling other NAD-dependent protein 
families such as the Sirtuins or PARPs, NAMPT directly contributes to tumor progression in 
colon cancer. Since NAD+ is a rate-limiting cofactor for the Sirtuins, its modulation is 
emerging as a valuable tool to regulate Sirtuin function [213, 214]. SIRT1 tends to either 
activate or repress transcription of specific target genes by H3 deacetylation at lysine 
residues [215] and has been suggested to be involved in cancer in a context-
dependent manner [151]. As SIRT1 has a direct NAD-dependent mechanism of action, 
we wanted to explore the causal role of SIRT1 in NAMPT-related colon cancer. By using 
sirtinol, we significantly decreased the protumorigenic and cancer stem cell-like 
properties and the transcriptional panel for stem cell markers genes and EMT effectors 
induced by NAMPT. The data confirmed that SIRT1 mediates NAMPT-induced 
tumorigenic properties and the activation of both stem cells and EMT transcriptional 
cores in the human colon cancer context.  
 
Similarly, NAD+ is also known to be a co-substrate of ADP‐ribosyltransferases (e.g., 
PARPs). PARP proteins have also been suggested to have a significant impact on 
cancer progression [53]. By using bioinformatic approaches and the PARP inhibitor 
olaparib, we found a strong correlation between the NAMPT-induced tumorigenic 
properties and the activation of both stem cell-like properties and PARP proteins. 
 
Therefore, our data reinforces the hypothesis that, by modulating SIRT1 and PARP1, 
NAMPT controls cellular functions that promote proliferation and pathways, thus 
regulating EMT and tumor dedifferentiation/reprograming. 
 
We explored whether an NAMPT-dependent profile comprising NAMPT, together with 
SIRT1 and PARP1 as mediators, and YAP1, MYC, DVL2, MMP7, CSNK2A1 and ADAM17 as 
endpoints of CSC pathways activation, enables a good stratification of the 
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chemotherapy response in patients. Our data clearly showed that this NAMPT-
dependent profile accurately separated patients with good prognosis from those with 
poor prognosis. In contrast to previous studies [216], our profile that included only gene 
expression was independent of the levels of intracellular NAD.  
 
As aforementioned, inhibition of NAMPT can lead to the depletion of NAD+, which in 
turn inhibits ATP synthesis. This effect eventually causes the attenuation of cancer cell 
proliferation and death [153, 192, 211]. Because NAMPT induces the CIC phenotype, 
we tested whether tumorspheres, as in vitro surrogates for tumor CICs, respond to the 
NAMPT inhibitor FK866. We found that this toxicity driven by the NAMPT inhibitor could 
be strengthened in combination with either sirtinol or olaparib. We found that colon 
tumorspheres are sensitive to NAMPT inhibitors, particularly tumorspheres with high levels 
of NAMPT expression, which indicates that NAMPT inhibition may be a suitable therapy 
for colon cancer. Therefore, inhibition of NAMPT in cells with high levels of this gene may 
contribute to inhibit the induced dedifferentiation-reprogramation and therefore drus 
resistance. 
 
Altogether, our data suggest that NAMPT may be a suitable therapeutic target for 
colon cancer too, especially in patients with poor prognosis who express this signature. 
We provide evidence that our gene signature may potentially facilitate the 
classification of patients in a molecular setting and predict good-responders to NAMPT 
inhibitors, with a particular effect on CICs subset.  
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9. CONCLUSIONS 
1. NAMPT is overexpressed in tumors of diverse origins. NAMPT could be used as a 
prognostic marker in colon cancer and glioma,  
2. NAMPT, stably overexpressed in tumor cells, is capable of enhancing tumor 
growth both in vitro and in vivo, invasiveness and cell death resistance. 
3. NAMPT increases the cancer stem cell phenotype measured as transcription of 
stem cell genes, increased number of holoclones, tumorspheres and increased 
levels of CSC-like markers such as CD133 and CD44. 
4. NAMPT overexpression favors EMT processes measured by related transcription 
factors for this transition. 
5. NAMPT overexpression confers increased chemoresistance and its inhibition 
recovers chemo sensibilization in full culture or tumorspheres. 
6. NAMPT, finally, is able to associate with gene signatures expression of factors 
mediating pathways controlling CSC-like properties, offering a mechanism to 
predict patient’s overall survival and potentially, response to treatment.  
7. Inhibition of NAMPT reduces growth of tumors cells, alone or in combination with 
drugs commonly used for gliomas or colon cancer. Furthermore, also reduces 
growth of tumorspheres as functional assay of CSC. 
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